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Abstract 
Keloid scarring is an extremely challenging form of abnormal scarring and the underlying 
biological mechanisms in its pathogenesis have not been established. There are multiple existing 
therapeutic approaches but all have a varying response with none showing a consistent advantage. 
Keloid-derived fibroblasts are observed to exhibit resistance to apoptosis during the course of scar 
maturation. In order to gain an insight into the pathological apoptotic regulation of keloids scars, 3 
pairs of normal skin and keloid scar fibroblasts derived f rom tissue samples collected from the same 
patients were analyzed for significant difference in the expression of apoptotic related genes using 
microarray. The microarray results were then confirmed using real time RT-PCR analysis. In this 
study, 5 genes were identified to be differently expressed in normal skin and keloid scar derived 
fibroblast, namely DcR3, Fn 14, TNFR2, DcR2 and OPG. These genes all play crucial roles in the 
regulations of wound healing and scar formation. In addition, the treatment modality that can 
potentially modulate the apoptosis regulation in keloid was also investigated in the study. The 
Nd:YAG 532 nm laser is an emerging modality for the treatment of keloid scarring. Previous 
studies by our group have shown that the QS 532 nm Nd:YAG laser is able to regulate gene 
expressions in normal fibroblast cultures. Further to this observation, the biological effects of 
Nd:YAG 532nm laser radiation on cell death and proliferation in keloid-derived fibroblasts were 
investigated in this study. Monolayer cell cultures of keloid scar fibroblasts were irradiated with the 
QS 532 nm Nd:YAG laser with different energy. Irradiated cells were analyzed for changes in cell 
viability, proliferation and apoptosis at 24 and 48 hours after laser treatment. The results showed 
that the QS 532 nm Nd: YAG laser can induce apoptosis in keloid-derived fibroblasts and the 
percentage of necrotic cell death was relatively low. It indicated that this laser may potentially 
induce apoptosis within a keloid lesion and trigger only minimal inflammatory response, and hence 







基因陣列中表現出顯著差異的基因’當中包括D C R 3，F n 1 4 , T N F R 2，D c R 2和O P G，並且以 
real-time PCR進行驗證。文獻指出這些基因都在創傷癒合和瘢痕疙瘩形成的過程中發揮著關 
鍵的作用。除此之外，是次硏究亦嘗試了解現有的治療方法對成纖維細胞的細胞凋亡過程的 
影響。波長532 n m 的 N d ： YAG激光輻照是一種治療瘢痕疙瘩的新療法。跟據本硏究小組 
過往的研究顯示，波長532 nm的Nd ： YAG激光有改變正常成纖維細胞的基因表達的能力， 
所以在是次硏究中我們嘗試更詳細剖析Nd ： YAG 532 nm激光輻照對瘢痕疙瘩的成纖維細 
胞的影響。爲了對比成纖維細胞的生長，壞死以及凋亡在激光輻照前後的變化，我們對瘢痕 
疙瘩的成纖維細胞施行不同能量的QS 532 nm Nd ： YAG激光輻照。結果顯示，在輻照後的 
4 8小時內，Nd ： YAG532 nm的激光可有效誘導瘢痕疙瘩的成纖維細胞凋亡而並非壞死。 
這意味著，Nd ： YAG532 nm的激光有可能是一種低炎症反應的治療方法，從而減低瘢痕疙 
瘩復發的機會。 
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Chaptel·l 
1 Introduction to I{eloid Scarring - The 
Pathogenesis and Treatment 
1.1 The Pathogenesis of Keloid Scarring 
The term keloid was first used by Alibert in 1806, and is derived from a Greek word 
Ineaning the "crab claw", which shows a resemblance of the scar being red, raised and 
with protrusions extending sideways around the boundary. Keloid scarring is unique to 
the human race, and this makes keloid research particularly difficult due to the lack of 
anilnal models (Kelly, 2009). Keloid is characterized by a scar that proliferates beyond 
the Inargins of the wound. Clinically, keloid is defined as a raised, erythematous, pruritic, 
fibrous lesion that will grow beyond the original boundary of the wound. This is also the 
most important clinical feature of keloid. While normal scar will mature gradually, 
appearing paler, softer and decrease in the scar volume, keloid scar on the contrary, will 
proliferate and remain active for a prolonged period of time and does not regress. 
Patients often report itchiness or pain in active Keloids. Therefore, keloid scarring is 
often described as a benign dennal fibroproliferative tumor, however with no malignant 
potential (Butler et aI, 2008). 
Keloid scars are rnost commonly found on the chest, shoulders, the upper back, the neck 
and the earlobe. There is an increasing incidence with an increase in racially defined 
pigmentation (Brown et aI, 2008; !vlarneros et aI, 2001). Keloid is observed usually 
following injury, such as acne, vaccination, burns, surgical wound healing and 
lacerations etc, and it commonly develops 1nonths to even a year after the injury (Juckett 
et aI, 2009). Despite the research efforts of nurnerous scientists across the world, the 
aetiology of the keloid remains unclear. The mechanism of the developlllent appears to 
be a result of an abnormal wound healing process, which leads to the fibroproliferati ve 
disorder. This may include the imbalance between degradation and production of the 
extracellular matrix, abnormal cell migration, proliferation and elimination (Seifert and 
Mrowietz, 2009). 
Wound healing is a very complex, yet carefully regulated process that involves a large 
number of cells and molecules. When injured, the release of intracellular factors into the 
extracellular fluid will activate the surveillance inflammatory cells to trigger the immune 
response. In the early phase of wound healing, the inflammatory cells will 
release pro-inflammatory cytokines and gro\vth factors to induce angiogenesis and hence 
increase blood supply to support tissue repair. These cytokines will also activate 
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fibroblast proliferation and increase synthesis of coIJagen for the formation of 
granulation tissues, which will eventually develop into a scar (Velnar et ai, 2009). 
When the inflammation response subsides, active inflammatory cells will be 
removed mainly via apoptosis, an important pathway used to remove unwanted cells by 
letting them "commit suicide" (Rai et aI , 2005). The level of cytolGnes and growth 
factors will hence return to the basal level. To avoid excessive production of scar tissue, 
endothelial cells that formed the small blood vessels will be removed to reduce the 
supply of oxygen and nutrients to the scar. Active collagen synthesizing fibrobIasts will 
also be removed as the scar matures. Collagenase activity will increase and hence reduce 
the fibrous mass within the scar and decrease the scar volume (VeInar et aI , 2009). 
There are in vitro studies suggesting that keloid-derived fibroblasts showed 
overproduction of pro-inflammatory growth factors, particularly TGF beta (Robles et aI, 
2007; Seifert and Mrowietz, 2009; Shih et aI , 2009). This group of growth factors plays 
an important role in inducing collagen production and fibroblasts proliferation. The 
over-expression of the receptor of TGF beta has al so been observed in keloid-deri ved 
fibroblasts. Other studies report that fibroblasts isolated from keloid scars are 
more sensitive towards TGF beta activation vvhen compared with normal fibro blasts 
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(Shih et aI, 2009; Jagadeesan and Bayat, 2006). However, although the role of TGF beta 
in keloid formation sounds prolnising, it is considered to be a result instead of the cause 
for the wound healing defect (Calnpaner et aI, 2006). 
Other studies suggest that the forn1ation of keloid scars is related to the abnormal 
balance between apoptosis and proliferation of fibroblasts (Lu et aI, 2007; Luo et aI, 
2001; Ladin et aI, 1998). At the end of the wound healing cascade, excess acti vated 
fibroblasts in granulation tissue are eliminated by apoptosis (Greenhalgh, 1998; Chodon 
et aI, 2000). When the population of fibroblasts in granulation tissue is eliminated, it 
\vould develop into relatively acellular mature scar tissue (Velnar et aI, 2009). It is often 
hypothesized that keloid scar derived fibroblasts exhibit reduced apoptotic behavior, and 
hence lead to an imbalance between collagen production and degradation, ultimately 
resulting in excessive proliferation of the scar. Reduced apoptosis of keloid-derived 
fibroblasts has been observed in Inany in vitro studies (Lu et aI, 2007; Luo et aI, 2001; 
Ladin et aI, 1998; Chodon et aI, 2000). However, the exact mechanism of how keloid 
scar fibroblasts develop such resistance to apoptosis is yet to be elucidated. 
1.2 The Impact of Keloid Scarring 
6 
Keloid scars are seldom life threatening; however, the scar can grow large enough to 
cause disability, affecting mobility and joint movelnents. As a result of piercing and 
tattooing, keloids cOlnmonly develop in visible anatomical sites such as the earlobes and 
the upper part of the body, causing significant aesthetic deformity. Thus, although the 
disease itself is not life threatening, it can greatly affect the quality of life of the patients. 
In 2005, Bock et al recruited 100 outpatients with keloid and hypertrophic scars and 
demonstrated that the presence of the scar caused a greater psychological than physical 
effect on the patients. Patients comlTIonly suffered from strong feelings of rejection and 
low self-esteem, especially in the younger age groups with decorative piercing. Also, the 
lack of satisfactory and reliable treatment contributes to the general negative feelings 
experienced by patients. 
1.3 The Treatment of I{eloid Scarring 
There are a wide range of therapeutic interventions that have been tried in the treatment 
of keloids. The more commonly used modalities being 1) the application of si licon gel 
sheets, 2) intralesional steroid injection, 3) cryotherapy, 4) laser therapy and 5) surgical 
excision followed by radiation therapy. Numerous studies have been published to 
support the efficacy of the various treatlTIent modalities; however, very few \-vere shown 
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to be clinically significant. These studies typically employed neither placebo control nor 
blinding of the participants, with a short follow up period and small numbers. Moreover, 
it is difficult to quantify the improvements of the scars and little evidence-based 
techniques have been used (Robles et aI, 2007). In 2006, Leventhal et al analyzed 39 
studies that covered 27 different treatments for keloid. The group concluded that the 
effect of the treatments on improving keloid was not statistically significant. Therefore, 
it is still believed that none of the cun~ent treatments can be proved to have a predictably 
significant benefit on the clinical condition. 
1.3.1 Silicon Gel Sheeting 
While surgical excision of keloids is a straightforward modality that can provide 
immediate cosmetic correction, the recurrence rate is typically above 80 percent (Mustoe 
et aI, 2002) and often leads to the potential for a larger keloid (Poochareon & Berman, 
2003). Therefore, surgical excision is seldolTI used alone for treating keloid. The 
application of silicone gel dressings after surgical excision is one of the most common 
treatments adjuvant therapies (Juckett et aI, 2009; Seifert et aI, 2009). It is non-invasive 
and relatively inexpensive with positive evidence for its efficacy. In 2002 an 
international advisory panel on scar management recoffilnended silicone gel sheet 
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therapy following surgical closure for the prevention of keloid and hypertrophic scar 
development (Mustoe et aI, 2002). It is particularly useful for children who have a low 
tolerance for pain. In 2001, de Oliveira et al studied the effect on silicone gel sheets on 
scars and concluded that the scars appeared softer with reduced erythema, pain and 
itching. However, silicone gel sheeting was generaUy more effective on Hypertrophic 
rather than Keloid scars (Borgognoni, 2002). 
1.3.2 Intralesional Steroid Injection 
Intralesional steroid injection is considered as one of the first-line therapies for keloids. 
The recurrence rate is reported as 9 to 50 % (Juckett et aI, 2009; Seifert et aI, 2009; 
Mustoe et aI, 2002). The treatment results of steroid injection can be ilnproved when 
combined with surgery or cryotherapy (Robles et aI, 2007; Seifert et aI, 2009; Berman & 
Flores, 1997). Triamcinolone acetonide is typically used, and it is clinically shown to be 
able to help soften the scar and reduce pruritus and tenderness (RobIes et aI, 2007). 
However, the pain associated with the intraIesionaI steroid injection is one of the major 
drawbacks (Kelly, 2004; Musto et aI, 2005). Also, up to 63 % of patients experienced 
side effects such as skin atrophy, hypo- or hyper-pigmentation, and the development of 
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telangiectasias (RobIes et aI, 2007). Therefore, intralesionaI steroid injection is not 
recoLlllnended for large keloid scars that require multiple injections. 
1.3.3 Cryotherapy 
Cryotherapy can be used alone or just before intraIesional steroid injection to enhance 
the effects of the injection by inducing ederrla (Seifert et aI, 2009; Lahiri et aI, 200"1). 
There are reports showing that cryotherapy was able to induce keloidal fibroblast 
differentiation towards a more nonnal phenotype and hence reducing collagen synthesis 
(RobIes et aI, 2007; Dalkowski et aI, 2003). However, permanent hypo-piglnentation or 
hyper-pigmentation and skin atrophy is the COlnmon side effect (Kelly, 2009). Therefore, 
the therapy is not recomrnended for the darker skinned nations (Mustoe et aI, 2002). 
Moreover, there is considerable pain and prolonged healing following the treatment 
(Kelly, 2004). Cryotheraphy is hence limited to the treatment of very small scars such as 
post acne scalTing. 
1.3.4 Radiotherapy 
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Radiotherapy can be used alone or in combination with the surgical removal of scars. 
Due to the concern that the radiation may induce carcinogenesis, this is usually 
considered as the last resorts for treating keloid when the scar is not responsive to other 
therapies. In one retrospective study (Ragoowansi et aI, 2003), radiotherapy at 24 hours 
after surgical removal of keloid scars gave 80 % success rate with no recurrence of 
keloid at 5 years follow-up. Ogawa et al in 2003 also reported a 77 % success rate after 
18 months follow-up. 
However, besides the side effects of radiation therapy: erythema and hyper-pigmentation, 
the risk of carcinogenesis still remains the major concern for such therapy. Therefore, 
radiotherapy is not recommended for children and young adults (Botwood et aI, 1999). It 
should be used for very severe keloids that are resistant to other therapies only 
(Ragoowansi et aI, 2003). 
1.3.5 Laser Treatment 
The use of laser is a relatively new ITIodality used in treating Keloid. The most 
promising results so far have come from the use of the Nd: Y AG lasers (neodyrnium: 
yttrium-aluminum-garnet laser) and pulsed dye lasers (Mustoe et al 2002; luckett et al 
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2009; Seifert et aI, 2009; Tanzi & Alster, 2004) . These lasers produce specific 
wavelengths of electrolnagnetic energy and are believed to be able to selectively destroy 
targeted structures in the skin. The use of the pulsed dye laser in conjunction with 
intralesional steroid injection has been reported to help to soften the scar and enhance 
the effects of steroid (Connell & Harland, 2000). In 2000, Kumar et al recruited 17 
patients with keloids for Nd: YAG laser treatment. The group reported that nearly 60 % 
of the patients showed flattening of the scar with no recurrence of keloid for up to 5 
years follow-up. Laser therapy was considered as an emerging treatment for keloid 
with potentially promising results (Mustoe et aI, 2002). Its efficacy is yet to be 
confirmed by longer term follow-up and larger scale studies. 
1.4 Summary 
To conclude, little consistent success has been observed in the wide range 
of current therapies applied to keloid scarring, and each method has both drawbacks and 
benefits. Laser treatment for keloid scars, particularly those utilizing pulsed dye lasers 
and Nd: Y AG lasers has gained popularity as emerging modalities for the management of 
keloid. Benefits of the method include being non-invasive, with little side effects. Laser 
of various frequency and intensity can possibly exert different effects on keloid, and 
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hence making it a potentially flexible treatJnent for keloids with different sizes and 
severity. Clinical studies using laser have already showed promising results on 
improvenlent of keloid scars. However, the mechanisms of the biological effects on 
tissues still remain unknown. In this thesis, the biological effects of 532 nm Nd: Y AG 
laser using different energy levels on keloid-derived fibroblasts are investigated as to 
explore the possible mechanism of action of laser irradiation. 
Furthermore, in the literature, a poor understanding on the pathology of keloids also 
makes the development of reliable therapies difficult. Without the support of sufficient 
biological research, treatments are typically developed by experience from clinical 
practices and this may be one of the reasons why existing treatments can seldolTI have 
consistent success with different keloid scars. It is very ilTIportant to understand the 
fundamental pathogenesis in order to develop a more promising treatment for keloid. 
Ideally, cells, molecules or other external factors that directly lead to the formation of 
keloid scars have to be identified and targeted to yield effective treatment results. Given 
the observation that keloid-derived fibroblasts exhibit resistance to apoptosis during the 
course of scar maturation, the mechanism of how these cells develop such 
resistance may be the key in understanding the pathology of keloid. In order to gain an 
insight into the pathological apoptotic regulations of keloids scars, the apoptosis-related 
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gene expression profiles of keloid and norrnal fibroblasts are cOlnpared usi ng 
microarray. The results can possibl y help our understandings of the aetiology of the 
mysterious keloid scarring. 
1.5 Aim of the study 
The aim of this study is two fold. First of all, the pathological apoptosis regulation of 
keloid fibroblasts is investigated. The expression profiles of apoptosis-related genes of 
keloid scar and normal skin derived fibroblasts are compared and studied by using 
ffilcroarrays. 
Secondly, the effect of Nd:YAG 532 nln laser on keloid-derived fibrobl asts is studied. 
Nd:YAG 532 nm laser is an emerging modali ty to treat keloid scalTing. In thi s study, the 
biological effects of Nd: Y AG 532 nm laser radiation on keloid-derived fibroblast, 
including proliferation and apoptosis, are investigated. 
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2 Apoptosis and Keloid P~ltll01ogy 
2.1 Introductioll 
2.1.1 Apoptosis - an overview 
Apoptosis or programlned cell death plays a critical role in nature. It is required during 
embryonic development, normal cell turnover and wound healing. It also plays 
important roles in the regulation of the imlnune system in response to physiological 
stimuli. It is also a process by \vhich the cell 'comlnit suicide' in response to cell stress, 
cell damage or conflicting cell division signals (Evan & Littlewood, 1998; Nagata, 
1997). 
The maintenance of tissue function depends on the balance of the cell number which is 
controlled by apoptosis. Too much or not enough apoptosis can hence be very hannful. 
For example, cancers cells are difficult to be eliminated because they fail to respond to 
apoptotic signals. On the other hand, excessive apoptotic activity in neurons can lead to 
neurodegenerati ve disorders such as Parkinson's diseases (Thompson, 1995; Haass, 
1999). Autoimmune disorders and central immune system phenomena are also related to 
the malfunction of the apoptotic control, which leads to failure in the elimination of 
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self-reactive lyrrlphocytes and active j n1mune cells after successful immune responses 
(Ashkenazi & Dixit, 1998). 
Apoptosis is a single cell event that will not affect the neighboring celJs. It is a cell death 
event characterized by a specific degradation of the cell's DNA and the loss of 
specialized membrane structures without triggering a significant inflammatory response 
(Rai et aI, 2005). Central to apoptotic cell death is a falnily of proteases called caspases 
(cysteine-containing aspartate-specific proteases). A more complete understanding of the 
important role of these proteases play in apoptosis only began to emerge in the late 20th 
century (Adams & Cory, 1998; Ashkenazi & Dixit, 1998). Under normal circumstances, 
caspases are present as inactive proteins. These proteins are very powerful when 
activated and can cause massive destruction of key target proteins important to the 
survival of a cell. Therefore, there must be sufficient control over the activation of these 
proteins before a cell is irreversibly cOJnmitted to apoptotic death. It is regulated under a 
number of pathways involving a huge number of molecules. 
Apoptosis signals are regulated and transmitted either via the apoptotic receptors on the 
cell membrane (the extrinsic pathway) in response to external stress, or initiated from 
within the cell (the intrinsic pathway) following an order to "commit suicide" (Rai et aI , 
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2005;Ashkenazi & Dixit, 1998; Andera, 2009). Through interactions of the molecul es 
via different pathways, the "initiator caspases" (caspase 8 and 9) can be acti vated. The 
acti vated "initiator caspases" will in turn activate the "executioner caspases" (caspase 
3,6 and 7) to execute apoptosis. Once the executioner caspases are activated, they will 
seek out and cleave their respective protein targets, hence dismantling the cell (Andera 
2009; Lavrik et aI, 2009; Nagata, 1997). 
2.1.2 The role of apoptosis in wound healing 
The role of apoptosis in wound healing was discussed in a review article written by Rai 
et al in 2005. Immediately following injury, surveillance neutrophils that reside in the 
tissues will quickly arrive at the injured sites. Cytokines are released to induce the 
proliferation and maturation of other inflammatory cells and start the wound healing 
cascade. Necrotic cells are relTIoved and our immune system is activated to defend the 
body against invading mjcroorganisms. When the wound healing response is initiated, 
neutrophils will be eliminated through apoptosis and consumed by macrophages to 
control and prevent a further inflammatory response. And finally, macrophages will also 
be eliminated by apoptosis when inflammation is down-regulated and a scar is formed as 
the end result of the wound healing cascade (Antoniades et aI, 1994; Tidball et aI, 1996). 
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Apoptosis is not only important in the regulation and control of the infl ammatory cell s, 
during the wound maturation phase, apoptosis is also crucial in determining the quality 
of the scar formation. The active granulation tissue consists of Inainly active fibroblasts 
and collagen supplied by small blood vessels created during the active phase of the 
'vvound healing. When the scar matures, popu lations of the activated cells have to be 
eliminated by apoptosis. The active fibroblasts that can produce collagen in the scar 
tissue will be suppressed and elilninated by the apoptosis signal so as to prevent 
excessive fibrous scar tissue formation (Green, 1997; Rai et aI, 2005). In addition, 
apoptosis signals are al so important in collagen degradation by inducing collagenase 
activity and reducing the fibrou s mass within the scar (Bian & Sun, 1997). 
2.1.3 Apoptosis Research on Keloids 
There are studies examining the differences in apoptosis regulation of keloids when 
compared with nonnal scar or normal skin . These differences are reported to lead to the 
failure in elimination of active fibrobl asts when the scar matures and results in the 
pathologic scarring. 
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Ladin et al (1998) obtained biopsies fro ln the center and the edge of keloid scars due to 
the observation that the scar is (nore acti ve at the edge then the centre. The group used 
the TUNEL technique to stain the ti ssue and found that the number of apoptotic cells 
was lower when cOlnpared to nonnal ski n. They also observed that the number of 
apoptotic cells decreased near the edge of the lesions. The group also performed 
experiments on monolayer fibroblast cultures and found that there was reduced 
apoptosis in keloid fibroblast cultures when compared with normal skin fibroblast 
cultures. 
Luo et al (2001) also performed experinlents on fibroblasts derived from both keloid and 
normal skin in a monolayer culture model. The keloid scars were horizontally divided 
into superficial, central, and basal groups and gave rise to three separate cell cultures. 
The number of cells that were undergoing apoptosis was identified using the TUNEL 
technique. Results showed that the number of apoptotic cells in keloid-derived fibroblast 
cultures of all the three regions was less than half when compared to that of normal 
fibroblasts. The group concluded that keloid-derived fibroblasts have reduced apoptosis 
when compared to normal fibroblasts derived from normal skin, which agreed with the 
results of Ladin et al in 1998. 
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Given the fact that keloid scars seldonl develop in the palm and sole, Chipev et al (2000) 
chose palmer fibroblasts fr0111 people with no keloid history as a control, and compared 
those with keloid fibroblasts. In his study both cell cultures were starved from serum 
supplement and the apoptotic behaviors of the cells were observed using Annexin Vand 
TUNEL assay. While nonnal fibroblasts underwent apoptosis due to serum starvation, 
keloid fibroblasts were resistant to the stress created. The group concluded that 
fibroblasts derived from keloids were lTIOre resistant to apoptosis when compared to 
normal skin. 
Lu et al (2007) raised Inonolayer cell cultures of fibroblasts isolated from peripheral and 
central area of keloid scars. The group induced Fas-mediated fibroblasts apoptosis using 
anti-Fas antibody in monolayer fibroblast culture models, and found that both peripheral 
and central keloid-derived fibroblasts v/ere resistant to Fas-mediated apoptosis. Such 
resistance was not observed in nonn al fibroblasts. Lu 's results agreed with Chodon et al 
(2000) in a similar study where Fas-mediated apoptosis was induced in monolayer 
fibroblast cultures. The group also found that the expression level of Fas-receptor was 
the same in the keloid and the nonnal control groups, suggesting that there luay exist 
some molecules in keloid that impair the Fas-mediated apoptosis pathway. 
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To summarize, studies that obtained punch biopsies of keloid scars revealed decreased 
apoptotic cells when compared with normal skin. The di stribution of the apoptotic cell s 
was decreased around the edge of the scars. Studies that used in vitro cell culture model s 
suggested that keloid-derived fibroblasts are refractory to apoptosis when cell stress was 
introduced. However, the exact mechanism of how this resistance to apoptosis is 
developed is yet to be understood. 
In order to further understand the pathogenesis of keloid scarring, the gene expression 
studies are required. The expression level s of a particular gene can be revealed using 
Northern blotting analysis. One of the lTIOst significant findings in the studies of gene 
expression was that keloid has a clear up-regulation of TGF beta gene that contributed to 
the excess production of collagen and the enhanced proliferation of fibroblasts (Chau et 
aI, 2005; Messadi et aI, 1998; Naitoh et aI , 2001; Phan et aI, 2003; Zhang et aI , 2004). 
These results are very promising; however they are often considered to be a consequence 
of an abnormal wound healing process instead of the cause (Campaner et aI, 2006). 
Apoptosis is another important area in the pathological studies in keloid. However, since 
the functions of many apoptosis-related proteins are not yet fully understood and are also 
heavily interrelated, studying the gene expression one by one is not effecti ve in 
revealing the full picture of the apoptotic pathways. Recently, the compari son of keloid 
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and normal fibroblasts in their apoptotic behaviors has been made more effective by 
cOlnparing the differences in the gene expression levels using ITIicroanoays. 
2.1.4 Microarray analysis of Keloid Scars 
Cell behavior is governed by protein production, vv'hich is in turn regulated by the 
transcription of mRNAs. In 1995, Schena et al were the first to extract mRNA from cells 
and quantify the relative expression levels using microarray. This publication has had a 
great ilnpact in biological research not only because it has made gene expression studies 
more effective by comparing thousands of genes simultaneously. More importantly, it 
enables researchers to study the inter-relationship between different genes and suggest 
their unique association to the disease (Chin et aI, 2006). 
Keloid researches utilizing rnicroarray began at the turn of the 20st Century. In 1999, 
Sayah et al recruited 4 keloid patients and another 4 normal volunteers with matched sex 
and age. 64 apoptosis-related genes were compared between the keloid group and the 
normal group, 8 apoptosis-related genes are identified to be differently expressed. 
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Chen et al (2003) compared 8400 genes in 3 patients vvith keloid scars, and the gene 
expression of each of theIn \vas nonnalized wi th the corresponding normal dermal 
fibroblast culture expression levels. The 8400 genes selected include collagen 
production genes, fibronectin and proteoglycan genes, growth factor and receptor genes, 
and apoptosis-related genes etc. 402 genes were shown to have different expression 
levels and that included 4 apoptosis-related genes: ASKl, KIAAOOI8, p21, and SARPl 
(secreted apoptosis-related protein 1). 
Satish et al (2006), on the other hand, compared 22284 genes in keloid scars deri ved 
from 3 patients, to 3 healthy individuals. The patients in the keloid group and the control 
group were randomly selected with different sex and age. The position where the skin 
samples were collected was also different. In their findings, 43 genes were 
over-expressed in keloid while 5 \vere under-expressed. Out of the 43 over-expressed 
genes, the ones that are related to apoptosis were ASY and PEA 15 (phosphoprotein 
enriched in astrocytes 15, shown to oppose Fas-induced apoptosis). 
A summary of competent recent papers using microarray to compare keloid scar and 
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11 th se studie reported th at sO lne apoptos is-rc latcd genes were differently ex pressed 
in kel ids. However, little consistency was fo und . AI 0 , the authors did not furth er 
di cuss how these express ion profil es nlay contribute to the pathology of keloid scar. 
In order to reveal a clearer picture of the apoptoti c regulation in keloid , in thi s study we 
used a cRNA gene array targeting on 11 2 apoptos is- rel ated gene to investigate 3 pair 
of keloid and nonnal skin ~ alnple ' obtained froln the ame patient. Gene that were 
differently expressed vvere identi fied, and the po sible rol e they play in kel oid calTln g 
are discussed. 
2.2 Material and methods 
2.2.1 Cell Culture 
All procedures were approved by the Clini cal Research Ethic Committee of the Chine e 
University of Hong Kong. Fibroblast cultures were obtained by explants techniques 
using keloid scar or normal skin tis ue specimens di scarded during surgi cal procedur s. 
Normal skin and keloid scar specilnens were collected fronl 3 patients 
Sample Gender Age 
ZYZ F 12 
LWS F 6 
101 F 46 
Skin specimens were collected in sterile grass bottles with Dulbecco's modified eagle 
medium (Gibco-BRL, Life Tech, CA, USA) containing anti-biotics and anti-mycotics 
solution: 100 Ulml penicillin, 100 ~lg/m] streptomycin and 250 ng/ml fungizone 
(Gibco-BRL, Life Tech, CA, USA). Di spase solution was prepared by dissolving 5 mg 
of dispase powder (Roche applied science, Germany) in 1 ml DMEM. The tissue sample 
was rinsed three times with phosphate buffered saline (PBS) and was immersed in the 
dispase solution overnight at 4°C. The dermis was separated from the epidermis by 
forceps and was then minced by scalpel and scissors into 1 - 2 mm cubes and evenly 
distributed on 100 mm tissue culture plates (Nunc, Rochester, NY). The tissue was 
incubated for 2 hours at 37°C, 5 % CO2, to facilitate explants attachment followed by 2 
ml FBS incubation overnight. The following day, 2 ml of DMEM containing 10 % FBS, 
100 Ulml penicillin, 100 J.lg/ml streptomycin and 250 nghnl fungizone was added and 
the final concentration of FBS in the nledium became 50 %. Medium was not changed 
during the first 4 days and afterwards, DMEM + 10 % FBS was used. Medium was 
changed twice a week until outgrowth of fibroblasts is observed. Fibroblasts were 
26 
subcultured by trypsinization using 0.25 % trypsin- EDTA (Gibco BRL) once 90 % 
confluence was reached and expanded in 1:5 ratio in DMEM + 10 % FBS. All 
fibroblasts used in this study were fronl passage 3 - 7. 
2.2.2 Microarray Analysis 
Isolation of RNA 
RNA was isolated using ArrayGrade™ Total RNA Isolation Kit (SuperArray Bioscience 
Corporation) according to the manufacturer's protocol. The filter columns, collection 
tubes, buffers and reagents were provided by the kit. 
5 x 106 cells were harvested froIn a 100 mnl culture dish. Cells were first pelleted in a 
1.5 ml RNase-free tube and lysed using 350 f.ll of Lysis and Binding buffer. The filtrate 
containing RNA was collected after 11000 g centrifugation for 1 min through a filter 
column. 350 f.ll of 70 % ethanol was added to the filtrate and was then desalted by 
adding 350 f.ll of Desalting Buffer followed by ] Inin of 11000 g centrifugation through 
a clean spin column. The spin column was washed 3 times using washing buffers 
provided by the kit followed by 30 s centrifugation at 8000 g. After the last wash, the 
tube was centrifuged for 3 min at 11000 g to dry the column completely. 50 f.ll 
27 
RNase-free water was added to the spi n co lurnn to dissolve the purified RNA, and it was 
collected in a RNase-free 1.5 1nl l11i crocentrifuge tube after centrifugation for 1 min at 
11000 g. 
The total RNA extracted was quantified by measuring the absorbance at 230, 260 and 
280 nm. 49 J-ll TE (pH 8.0) was dispensed into UV transparent microcuvette and 1 J-ll of 
RNA sample was added. 1.5 J-lg of total RNA of each sample was also characterized on a 
denaturing 2.0 % agarose gel containing ethidiulll bromide (0.5 J-lg/ml). The total RNA 
sample that contained sharp 28S and 18S rRNA bands and peaks without smearing was 
stored at -80 QC. 
cRNA Target Labeling for Oligo Hybridi zation 
For each RNA sample, 3.0 ~g of total RNA, 1.0 ~1 of TrueLabeling primer (Oligo 
GEArray Reagent Kit) together with RNase-Free H20 were added to a final volume of 
10 ~l followed by incubation at 70 QC for 10 min. Afterwards, 4 ~l RNase-free H20, 4 
~l of 5X cDNA Synthesis Buffer, ] ~l RNase Inhibitor and 1 ~l cDNA Synthesi s 
Enzyme Mix was added to each sample and was incubated at 42 QC for 50 minutes 
followed by 75 DC for 5 minutes then cooled to 37 DC. 16 ~l of 2.5X RNA Polymerase 
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Buffer, 2 J.ll Biotinylated-UTP Jnd 2 ~ll 10 IT1M RNA Polymerase Enzyme were mixed to 
a final volume of 20 J.ll at room tetnperature and was added to each sample. The tube 
was incubated for overnight at 37 QC to yield cRNA. 
cRNA purification was then performed using SuperArray ArrayGrade™ cRNA Cleanup 
Kit. 50 J.lI of RNase-free H20, 315 J.ll Lysis & Binding Buffer and 315 J.lI ACS-Grade 
100 % ethanol was added and centrifuged for 30 s at 8000 g through a spin column. The 
cRNA as filtration residue was washed t\vice using washing buffer followed by 
centrifugation for 30 s at 8000 g. After the last wash, the tube was centrifuged for 3 min 
at 11000 g to dry the column completely. 50 ~l RNase-free water was added to the spin 
column to dissolve the purified cRNA, and it is collected in a RNase-free 1.5 ml 
microcentrifuge tube after centrifugation for 1 mi n at 11000 g. 
Oligo GEArray® microarray 
A pre-wetted array membrane inside a hybridization tube with 2 ml of pre-warmed 
GEAhyb Hybridization solution was incubated inside the hybridization oven at 60 QC for 
2 hours with continuous agitation at 5 rpm. Afterwards, 3 J.lg of biotin-Iabeled cRNA in 
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0.75 ml pre-\\ armed GEAh. 'b H ybrjdi zati on Sol ution wa ' added fo r 0 emj ght 
incubation at 60 QC with acitati on at ,.. rprn . 
The following day, the array meln brane ,"a " ' \" hed \vith 5 ml \ a h Solution 1 
foll o\\ed by 5 ml Wash Solution 2 at 6J ~C " ith a:;i tation at 10 rpm for 15 mi nu .. e . 2 rrd 
GEAblocking Solution Q 'a added to the h .,-blidization tube and incub ated for -+ 0 min 
\ ith agitation at 10 rpm in room temp rature. L-\fter\\,ard ~ 2 ml Dilute AP-S A Buff r 
\ a added to the tube and 'a in ubat d f() r 1 r) min \\'ith agitation at 10 rpm. The 
membrane v; a then v. a hed "jth 4 m ] 1 :.' B uffer F fo r 5 min \\ 'i th agitation at - rpm or 
4 time and \\'a rin ed t \-i e \"jth -, ml Buff r G . Finally ~ 1.0 m l CDP-S tar 
chemilumine cent ub trate \'a added to the h 'bridization tube and \'a in uba ed or -' 
min at agitation 10 rpm. The m mbrane I:a" th n pI a ed into a pla~ tj heet pro ec 0 . 
Image \vas acquired by expo in _ the m ill ran:: o n a film for 1 - - minute dep ndin2' 
on the inten ity of the ic nal. 
2.2.3 Real-time peR 
cD ... ~ .A Primer for real -time peR , 'ere de-' .:: ne ~ u ing Light-C. ' ler Primer D esign 
ofu\'are ~ and the re pe ti 'e e ue e l:ere 0 11 0 \ ' : . 
TNFRSRF12A 
Human TNFRSF12A forward: CTGGCTCCAGAACAGAAAGG 
Human TNFRSF12A reverse: GGGCCTAGTGTCAAGTCTGC 
TNFRSRF6B 
Human TNFRSF6B forward : TCAATGTGCCAGGCTCTTC 
Human TNFRSF6B reverse: GCCTCTTGATGGAGATGTCC 
TNFRSFIB 
Human TNFRSFIB forward: GTCGGTAAGTTGAATGG 
Human TNFRSFIB reverse: TCA TGTCCTCATGTGG 
TNFRSFIOD 
Human TNFRSFIOD forward: AGTACTTGACCCATGC 
Human TNFRSFIOD reverse: GCCTAAAACGACCCTT 
TNFRSFIIB 
Human TNFRSFIIB forward: CCTAACTGGCTTAGTG 
Human TNFRSFIIB reverse: GTGAGGTTAGCATGTC 
According to the manufacturer's protocol, a master mi x for the LightCycler PCR 
reaction was prepared containing 5 J.ll PCR grade water, 1 ~ll forward primer (0 .5 J.lM), 
and 1 J.ll reverse primer (0 .5 J.lM), 2 J.ll LightCycler Fast Start DNA SYBR Green I 
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Master Mix (Roche Diagnosti cs). The In as ter 1li x was prepared in multiples of the 
volume described above sufficient for the total nu 11l ber of reactions to avoid pipetti ng 
error. 9 ~l of the LightCyc]er rnaster Jni x was pipetted into the Light-Cycler gl ass 
capillaries on a pre-cooled Li ghtCycler Salnpl e carousel, and 1~1 sample cDNA 'vvas 
added as a PCR template . 
Real time PCR Experimental run s were perfo rmed in duplicate under the follo wi ng 
conditions: Denaturation - at 95 °C for 10 ln in 
Amplification and quantifi cation (45 Cycles) - Single fluorescence measurement at 95 







Melting curve -fluorescence was conti nuously nleasured at 60 - 95 °C with a heating 
rate of 0.18 C/s. 
Cooling - 40°C 
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Results were analyzed using Light-Cycler Relative Quantification Software (Roche 
Diagnostics) and expressed as respective ratio vvith respect to GAPDH. 
2.2.4 Statistical 'Test 
The results were expressed in keloid/normal expression ratios. Under n=3, 2-sided 
Wilcoxon Signed Rank Test has been performed on the real-time peR results to test if 
the expression ratios were significantly different from 1. 
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2.3 Results 
2.3.1 Apoptotic gene profiles in keloid versus adjacent normal fibroblasts 
Based on the data obtained fronl the gene array, the expression levels of each gene were 
quantified and plotted as scatter plots by the GEA suit program. The genes expressed in 
keloid scar derived fibro blasts were plotted in the Y-axis against their correspond] ng 
normal skin as control in the X-axis. The significant level was chosen to be a 1.4 fo ld 
difference in expression level to screen out a reaso nable number of genes for further 
analysis. Apoptosis-related genes that are significantly different in expression levels 
have been identified and listed as below respectively for each pair of the three samples. 
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The first pair: 



















































Genes up-regulated in keloid difference 
Genes down-regulated in 
keloid 
CASP4 1.63 TNFRSFllB 
DAPK2 1.62 TNFRSF1B 
FASLG 1.66 
TRADD 1.41 











The Second pair: 
K2- (patient LWS) 
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Figure 2. Second pair of keloid scarf normal skin gene expression analysis 
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The third pair: 
K3- (patient ZYZ) 
Croup 4 vs. Group 3 
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3.01 3 .11 3 .21 3 .31 3.41 3 .51 
loglO (Group 3) 
Genes up-regulated 
in keloid· fold difference 
Genes down-regulated 
in keloid 
BAX 1.43 BNIP3L 
CARD8 1.40 TNFRSFIIB 
TNFRSFIOD 1.44 TNFRSFIB 
TNFRSF12A 1.53 
TNFRSF6B 1.84 












Out of the three pairs of samples, the genes that sho\ved significant difference in 





To further confirm the consistency in the difference in the gene expression levels, the 
averaged gene expression levels in keloid-·derived fibroblasts were obtained by groupi ng 
all keloid samples and taking the mean. They \vere compared to the average gene 
expression levels of normal ski n sarnples . The signi ficant level was chosen to be a 1.3 
fold difference in expression levels to screen out a reasonable number of genes for 



















































Genes up-regulated Genes down-regulated 
in keloid fold difference in keloid 
TNFRSF12A 1.40 TNFRSFIIB 
TNFRSF6B 1.45 TNFRSFIB 
TNFRSFIOD 1.35 
Figure 4. Analysis on the consistency in the difference in gene expression levels 








The 4 genes that were obtained using the pairwise comparisons were also found in this 
averaged analysis. This suggested that the difference in expression levels of these genes 
was significant and consistent. Real time peR has been performed to confirm and 
quantify the difference in expression levels. The results were as follows: 
Fold difference in gene expression 
TNFRSF100 TNFRSF118 TNFRSF18 TNFRSF68 TNFRSF12A 
K1/N1 2.00 0.31 0.36 1.86 1.54 
K2IN2 1.37 0.16 0.57 1.79 1.83 
K3/N3 2.76 0.88 0.84 3.59 4.89 
Average fold difference 2.04 - 0.45 0.59 2.41 2.75 
SO 0.69 0.38 0.24 1.02 1.86 
n=3 
p=0.109 for all groups (2-sided Wilicoxon Signed Ranks Test) 
Fold difference in Gene expression levels of keloid and their normal control 
TNFRSF10D TNFRSF11B TNFRSF1B TNFRSF6B TNFRSF12A 
Genes 
Figure 5. Results of Real Time peR analysis on gene expression 
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2.4 Discussions 
2.4.1 Gene Array Experimental Design Discussions 
The choice of normal control in gene array experiments was particularly important as it 
was acting as a threshold (baseline) for gene expression levels. Deviations from the 
threshold suggested there are up or down regulations of gene expression. Therefore, the 
genes identified in the microarray analysis were dependent on the choice of control 
grollp. Existing studies have been using various normal controls including:-
1) Adjacent normal skin from the same keloid patient (Chen et aI, 2003) 
2) Random normal skin from volunteers without keloid history with unmatched sex, age 
and site (Satish et aI, 2006) 
3) Normal skin from volunteers without keloid history with matched sex, age and site 
(Sayah et aI, 1999; Seifert et aI, 2005) 
Despite the importance of the normal control, many published papers failed to discuss 
the choice of their control. SOlne even failed to disclose the source of the normal sample, 
adversely affected the impact of the published results. 
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Studies that have chosen randolll norrnal skin satnple from volunteers with no keloid 
history as control have an obvious advantage that the salnpling bias could be removed. 
Provided that the normal pool is large enough and the volunteers are well chosen to be 
truly non-keloid-prone, the net effect of the individual variations can become very sl11al1. 
The group will then represent a characteristi c normal threshold of gene expression levels, 
and reveal the deviations in keloid lesions. 
However, given the relatively slllall exarnp]e size in general for keloid studies, it is 
questionable that whether the published papers could ever reach a scale that is large 
enough to remove the individual variations, which is essential for to the following 
reasons:-
1) The structure of skin changes drastically across ages. Therefore, the skin samples 
obtained from individuals with different age groups might not be comparable. 
2) The metabolic rate for the younger indi viduals is far higher than that of the 
elderly. Apoptosis-related gene expression may also be drastically different. Thi s 
potentially huge difference in apoptosi s-related gene expression levels can obscure the 
significance of expression level differences between the normal and the keloid. 
3) Skin quality such as thickness, color and strength varies in different parts of body. 
Therefore, skin san1ples obtained from different part of body with different quality might 
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not be comparable. 
Because of thi s, normal samples fronl individuals \vith matched age and sex may be a 
better alternative. However, in addition to the difficulties in collecting the samples given 
the tightened criteria, the normal pool neither represents a random normal control nor 
does it elilninate (though minitnized) indiv idual variations. 
For small sample size keloid scar studi es like ours, due to research constraints, using the 
patient's own normal skin as control would be the most effective, as individual 
variations are completely eliminated. COlnpari son results could clearly reveal the 
deviations of keloid-deri ved fibroblasts froln normal. Even small yet consi stent 
difference, which could be masked under compari sons with random normal controls, 
could be identified. However, since there has been reported family linkage for keloid 
formation, such research design may raise concerns on whether the normal skin of 




Gene Array Results Discussions 
The Death Receptors and Death Ligands 
Interestingly, all the genes identified in this study are apoptosis death receptors. Death 
receptors are involved in the extrinsic apoptosis pathway and will interact with the death 
ligands to Inediate apoptosis (Nagata, 1997; Andera, 2009). Death receptors mainly exist 
as a type I transmembrane protein, with an extracellular region interacting with the death 
ligands, and an intracellular region known as the death domain (Guicciardi and Gores, 
2009). When death ligands interact with their respective death receptor extracellularly, a 
cascade of intracellular events will be triggered through their death domain and will 
eventually lead to apoptosis. The Fas ligand (FasL, also known as CD95L), tumor 
necrosis factor (TNF) and TNF-related apoptosis inducing ligand (TRAIL) are subsets of 
death ligands and shared comparable protein structures (And era, 2009; Mahalingam, 
2009; Zhang et ai, 2000; Guicciardi and Gores, 2009). 
The death receptors such as Fas (receptor for FasL, also known as CD95 or TNFRSF6B), 
TRAIL receptor and TNF receptors are expressed in a wide range of normal cells (Gupta 
et aI, 2001). However, some death ligands are secreted lnainly by white blood cells only. 
For example, TNF is mainly secreted by activated T cells and macrophages while FasL 
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is mainly secreted by cytotoxic T cells and natural killer cells (Gupta et aI, 2001; Kurnar 
& McNerney, 2005; Strasser et ai, 2009). This is actually how white blood cells get rid 
of tumor cells, virus infected cells and badly damaged cells, by secreting death ligands 
and inducing apoptosis (Strasser et ai, 2009). However, the case is a little bit different 
for TRAIL. TRAIL is expressed in a wide range of normal cells which also have the 
TRAIL-receptors on their cell membrane (Zhang et aI, 2000; Mahalingam et aI, 2009). 
Therefore, to avoid induction of apoptosis that is not necessary, there must be a system 
to protect the cells. 
The tumor necrosis factor receptor superfamily (TNFR superfamily) consists of two 
main subgroups of receptors: the death receptors and the decoy receptors (Andera, 2009; 
Guicciardi and Gores, 2009). They are homolog proteins that are very similar in 
structure but serve very different functions. The death receptors generally have a death 
domain in the cytoplasmic regions. When activated, they are able to trigger a series of 
cytoplasmic events that would lead to apoptosis (Nagata, 1997); decoy receptors 
generally do not have an effective cytoplasmic region and will not be able to directly 
trigger apoptosis cascades (Ashkenazi & Dixit, 1999). Instead, they protect the cells 
from apoptosis by competing with the death receptors for death ligands. Over-expression 
of decoy receptors can potentially inhibit apoptosis under their respective pathway. 
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Death decoy receptor 1 and 2 (DcRI and DcR.2) are decoy receptors that have very 
similar structure when compared with TRAIL-RI and TRAIL-R2 respectively except for 
their cytoplasmic region (DcRl does not have a cytoplasmic region while DcR2 only has 
a truncated cytoplaslnic tail) (Zhang et aI, 2000; MahalingalTI et aI, 2009; Guicciardi and 
Gores, 2009). Note that the decoy receptor DcR2 is also known as TNFRSFIOD. The 
Fas decoy receptor is DcR3, also known as TNFRSF6B. Both of them are up-regulated 
in our study. 
2.4.3 Do"vn-regulations of TNFRSFIB in Keloid-derived Fibroblasts 
TNFRSFIB, more commonly known as TNFR2, is one of the two main Tumor Necrosis 
Factor receptors (TNF receptors). TNF plays important roles in activating and 
modulating body's inflamlnatory response. It is highly pro-inflammatory and its 
expression could be found in a wide range of cells in our immune system such as 
monocytes, Inacrophages, mast cells, T and B lymphocytes etc. (Bradley, 2008) 
TNFRl and TNFR2 are by far the lnost well known receptors for TNF. They are most 
commonly found on the surface of circulating T cells (Bradley, 2008). Besides TNF, 
TNFRl and TNFR2 can react with the same or completely unrelated molecules, adding 
46 
complexities into the role and the effects on interactions between the tvvo receptors. 
TNFRl is relatively well studied in ternlS of its activation pathways and function. Its 
activation will lead to pro-inflarnmatory responses and has been considered the main 
receptor for TNF, while TNFR2 was considered only acting an auxiliary function 
(Holtmann et aI, 2002). However, studies have emerged to suggest that there are 
differentials in expressions of the two receptors observed in various types of cells under 
different pathological conditions (AI-Larnki et al, 2001; AI-Lamki et aI, 2005; Hamid et 
aI, 2009), hinting that there may be unknown roles of TNFR2 in the inflammatory 
resp'onse yet to be discovered. More recent studies even revealed that TNFR2 appeared 
to signal both complementary and opposing effects to TNFRl (Bradley, 2008). 
AI- Lamki et al (2005) studied the effect of both receptors in normal kidney cells and 
obtained that TNF-TNFR 1 pathvvay could trigger tubular cell apoptosis while 
TNF-TNFR2 pathway promoted proliferation. Hamid et al in 2009 induced heart failure 
in wild type TNFRl -/- and TNFR2 -/- mice via coronary ligation. By examining the 
cardiomyocytes, the group obtained that TNRF1 exerted pro-apoptotic effects to the 
cells while over-expression of TNFR2 attenuated the apoptotic signals. 
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While the role of TNFR2 in kidney and heart muscle cells seems to be opposing 
apoptosis and inflamlnation, Kafrouni et al in 2003 demonstrated the opposite effect in 
the liver. The group studied the antiviral-immune response on TNFRl and TNFR2 
deficient mice. Results showed that down-regulation of TNFR2 exhibited decreased 
levels of FasL expression to combat virus. The group concluded that the TNF-TNFR2 
interaction was essential to anti-viral immune response in liver via the FasL pathway. 
Existing studies so far are not capable of drawing a concrete conclusion on the role and 
action of TNF-TNFR2 interactions. However, it is clear that TNFR2' s action is dynamic 
and heavily tissue specific. It may also depend on the availability of TNF and the 
relative abundance of TNFRl. In our studies we have identified a significant 
down-regulation of TNFR2 in keloid-derived fibroblasts when compared with normal. 
Whether or not the observation contributes to the apoptotic defects of keloid lesions still 
remains to be unfolded. 
2.4.4 Up-regulations of TNFRSFIOD in Keloid-derived Fibroblasts 
TNFRSFIOD is more commonly known as DcR2, a member of the TRAIL pathway. 
The TRAIL pathway is a very interesting apoptosis pathway. It was first discovered by 
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Wiley et al in 1995. Soon after its discovery, the unique feature of the apoptosis pathway 
was quickly revealed. TRAIL has been shown to be able to induce apoptosis in 
transformed cells, for example the cancer cells, but have minimal cytotoxic effects on 
normal cells (Mariani & Kramlner, 1998; Walczak et aI, 1999). It has drawn 
considerable attention throughout the years and has been studied as a potential 
therapeutic target for treating cancers (Mahalingam et aI, 2009). 
TRAIL is mainly expressed by activated T cells. It exerts its apoptotic function via 
interacting with the death receptors on cell surface, DR4 and DR5 (Chaudhari et aI, 
2006). Earlier studies often speculate the decoy receptors DcR 1 and DcR2 may play 
major roles in protecting the normal cells from apoptosis (Wiley et aI, 1995; Pitti et aI, 
1996). Cancer cells, on the other hand, may express less decoy receptors when compared 
with death receptors and hence become more susceptible to TRAIL-induced apoptosis 
(Mahalingam et aI, 2009). 
However, more recent studies revealed that the protection mechanism on normal cells 
was far more complicated than what had been expected. For example, 10 et al in 2000 
demonstrated that TRAIL induced significant apoptosis in normal human hepatocytes. 
The group concluded that any cancer therapies targeted on TRAIL was not suitable for 
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treating liver cancer. Furthermore, Zhang et al in 2000 studied the effect of TRAIL on 
varies types of norm al cells including fibroblasts from human lung, rnelanocytes, and 
hun1an ulnbilical vein endothelial cell s. The group demonstrated that all the three types 
of nonnal cells were resistant to TRAIL induced apoptosis. However, the rnechanism for 
developing such resistance varied across the different types of normal cells. Human 
umbilical vein endothelial cells mainly cOln bated TRAIL via the expression of the 
TRAIL decoy receptor DcR 1. The group showed that removal of the decoy receptor 
could increase the cells susceptibility to TRAIL induced apoptosis. On the contrary, the 
group could only observe expression of TRAIL death receptor DR5 on normal hU111an 
fibroblasts, while the expression of decoy receptors DcR1 and DcR2 were not detectable. 
While normal fibroblasts were shown to be resistant to TRAIL induced apoptosis, the 
protection did not seem to come from the decoy receptors alone. In their studies the 
group tried to determine if there is any other TRAIL inhibitors existed which contributes 
to the resistance. However, the n10lecules covered under the scope of the study were 
only minimally detectable. 
While Jo et al (2000) demonstrated that nOrIn a1 fibroblasts isolated from lung only 
expressed the death receptor DR5, Miyashita et al in 2004 observed that fibrobl asts 
isolated from rheumatoid arthritis, an auto-imn1une di sease, expressed both DcR l and 
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DcR2. Synovial fibroblasts isolated frorn rheutnatoid arthriti s are known to show 
resistance to apoptosis. However, the group did not compare the expression level s of the 
decoy receptors with the normal counterpart as control, nor did they determine whether 
the cells' resistance to apoptosis was related to the expression of the decoy receptors. 
We are the first group to observe an up-regulation of TRAIL decoy receptor DcR2 
up-regulation in keloid scar derived fibroblasts. Frotn existing studies, we have 
determined that nonnal fibroblasts express lnore death receptors on TRAIL than decoy 
receptors on the cell surface; whereas fibroblasts isolated froIn autoimmune disease 
rheumatoid arthritis expressed both decoy receptors. While the role of the decoy receptor 
DcR2in controlling the TRAIL-induced apoptosis remains unknown, further studies are 
required to reveal the relationship between the pathology of keloid formation and the up 
regulation of DcR2. Nevertheless, it opens a novel research possibility in understanding 
the apoptotic behaviors of the pathologic cells. 
2.4.5 Down-regulations of TNFRSFIIB in Keloid-derived Fibroblasts 
TNFRSFIIB is more commonly known as OPG, or osteoprotegrin, which means the 
bone protector. It is another member of the tumor necrosis factor receptor superfaInily 
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and is a soluble protein secreted by the cell (Yasuda et aI, 1998; Tsuda et aI, 1997). It 
was first discovered by Simonet et al in 1997, and its role against bone resorption has 
been quickly revealed. 
R.ANI( (Receptor acti vator of nuclear factor K B) is a transmembrane receptor, which is 
also known as TRANCE Receptor, pri marily secreted by dendritic cells and skeletal 
tissue such as bone and skeletal muscle (Anderson et aI, 1997; Nakagawa et aI, 1998). 
Once activated, it can stimulate osteoclast transfonnation from its precursor cell to the 
mature osteoclast (Takahashi et aI, 1999; Fuller et aI, 1999). RANK ligand, also known 
as TRANCE, is a signal transducer of the RANK pathway and it is shown to be able to 
mediate osteoclastgenesis and hence bone resorption (Yasuda et aI, 1998). OPG on the 
other hand, can compete with RANI( and inten~upt the cell to cell signal transduction, 
and hence inhibiting osteoclast Inaturation and activation, which in turn protect the bone 
from resorption.(Simonet et al ] 997; Tsuda et aI, 1997) 
Interestingly, the R.A.NK-RANKL interaction is also closely related to our immune 
system. Besides skeletal tissues, RANKL is also highly up-regulated in activated T -cells 
(Wong et aI, 1997); while RANK is IllOSt cOlnmonly seen in dendritic cells (Anderson et 
aI, 1997) - cells in our immune system responsible for capturing and presenti ng antigens 
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to T-cel1 , and hence activating our ilTItTIUne respon se. In normal CirCUlTIstances, dendri tic 
cells have to be quickly removed by apoptosis after interacting with T-cells, via FAS or 
TRAIL pathway (Ingulli et aI, 1997). Failure in the apoptotic regulations will lead to 
excessive immune response or even autoimlTIUne diseases. Wong et al (1997) were the 
first to show that interaction between RANKL on acti vated T -cells and RANK on 
dendritics cells prolTIoted dendritic cells survival. Research by Josien et al (2004) also 
showed that RANKL treatment enhanced the persistence of mature antigen-presenting 
dentritic cells and increased the anti gen-specific T -cell response. 
OPG, the secreted and soluble decoy receptor for RANKL is speculated to be able to 
interfere with the RANK-RANKL interaction and hence down-regulating the immune 
response by removing the protection signals on dendritic cells (Leibbrandt et aI , 2008). 
Ashcroft et al in 2003 demonstrated that OPG can reduce dendritic cells survival and 
hence down-regulated T-cell mediated inflammation in IL-2 deficient 010use \vith 
autoimmunity. 
Our group has, for the first time, reported a down-regulation of OPG in keloid-derived 
fibroblasts when compared with normal fibroblasts. Given the important role of OPG in 
modulating the inflammatory response, particularly by reducing the survival of dendritic 
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cell s, we speculate that the down-regulation of OPG l11ay play a role in the pathology of 
the keloid disease. 
The keloid scar is characterized by a prolonged and over-reactive inflammatory response 
to\vards injury. A localized decrease in OPG secreted by keloid scar fibroblasts may 
contribute to the prolonged infl ammation. Further studies are required to investigate the 
role of OPG on the localized illlmune response of keloid patients and the keloid scar 
formation. 
254.6 Up-regulations of TNFRSF12A in Keloid-derived Fibroblasts 
TNFRSF12A, also known as Fn 14, is by far the sn1allestmember of the tumor necrosis 
factor superfamily identified. It has also the shortest cytoplasmic dOlnain of the entire 
family consisting of merely 28 amino acids (Ran et aI, 2003; Wiley et aI, 2001). The 
only known ligand that interacts with Fn14 is TWEAK (Ran et al, 2003). TWEAK was 
first discovered by Chicheportiche et al in 1997, together with its small receptor Fn 14 
which lacks a functional cytoplasmic domain. They were considered a weak apoptosis 
pathway and did not deserve much attention. 
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However, in stead of inducing apoptosis, Tweak-Fn14 is now shown to play an important 
role in lTIodulating tissue regeneration after injury (Girgenrath et a], 2006; lakubowski et 
aI , 2005). It is also believed to be related to various tissue pathologies associated with 
inflalnrnatory di seases (Charnbel1 et aI, 2004) . Over-expression of TWEAK and its 
receptor Fn 14 is able to arnplify the inflalumatory response. Abnormal expression of 
Fn 14 has been observed in autoimmune disease, or even cancers. (Chambell et aI, 2004; 
Burkly et aI, 2007) , 
TWEAK-FnJ4 in tissue injuries 
TWEAK is a soluble cytokine prinlarily secreted by most inflammatory cell types 
including monocytes, macrophages, dendritic cells and activated T -cells etc( Maecker et 
aI, 2005; Burly et aI, 2007; Wiley and Winkles, 2003). Fn14 on the other hand, is hard ly 
detectable in normal cells under nonnal situation. However, its expression was shown to 
be increased quickly following tissue injury (Feng et aI, 1999; Zheng and Burkly,2008) . 
Interestingly, Fn 14 expressions can only be found in cells under the epithelial , 
mesenchymal and endothelial lineages that altogether formed the building blocks of our 
body tissue (Girgenrath et aI, 2006; Meighan-Mantha et aI, 1999). However, its 
expression was not seen in T and B cells (Maecker et aI, 2005). Therefore, the 
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Tweak-Fn14 pathway is often thought to be a pathway how the systemic immune system 
exerts its control over the functional tissues. 
In 2005, J akubowski et al demonstrated that TWEAK is capable of simulating the 
proliferation of hepatic precursor cells after liver injury, hence suggesting the 
TWEAK-Fn14 pathway's important role on regeneration after tissue injury. 
In 2006, Girgenrath ,et a1 has induced injury by injecting cardiotoxin into Fn 14-deficient 
mice and found that the i nflamnlatory response was greatly reduced and delayed. The 
group has determi ned that Fn 14 expression is crucial for the proliferation of the muscle 
pro-genitor cells, which is essential for tissue repair after cardio-injury. Therefore, 
down-regulation of Fn 14 directly leads to deficiencies in the expansion of myoblasts and 
results in an unsuccessful wound healing response. 
Soon after tissue injury, the onset of wound healing response willlead to infiltration of 
inflammatory cells to the damaged site and the release of growth factors such as PDGF 
and FGF to promote tissue repair. These signals were shown to be able to trigger Fn 14 
expressions in the TWEAK responsive cells of various types of tissues, including the 
joint (synoviocytes and chondrocytes), the kidney (mesangial and glo1nerular/tubular 
epithelial cells), the skin (keratinocytes and fibroblasts), and the nervous systems 
(astrocytes and Schwann cells) (Kumar et aI, 2009; Chorianopoulos et aI, 2009; Burkly, 
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2007; Girgenrath et aI, 2006). With a hi gh level of Fn] 4 expression, these celJ s will 
hence respond to TWEAK Inediated proliferation initiated by inflammatory cell s for 
tissue repair. When the infl amlnation response subsides, the expression of both TWEAK 
and Fn 14 will return to their basal level when robust tissue regeneration is no longer 
required. However, in some pathological conditions, prolonged over-expression of Fn 14 
has been observed. The effect of the high leve l expression has been studied in many 
pathological conditions such as fibrous degenerati ve diseases, autoimmune diseases, and 
cancer (Jakubowsji et aI, 2005; Kalnijo et aI, 2008; Kumar et aI, 2009). 
Tweak-Fn 14 in pathological infl amlnations 
Many wound healing disorders and i nflalnmatory diseases often come with a 
self-sustained over-reactive inflammatory response localized within the target ti ssues . 
Studies have suggested that persistent elevated expression of TWEAKlFn 14 may 
contribute to the pathology. It may act as the effector molecule that links the disorder in 
inflammatory cells to specific tissues . 
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Jakubowski et a1 in 2005 has observed an up-regulated expression level of Fn14 in liver 
cirrhosis, a pathological condition where normal hepatic tissue is replaced by fibrous 
scar tissue. The expression was found in bile ducts and the fibrotic regions and was 
significantly up-regulated when cOlnpared \;\Iith normal liver. Furthermore, Jakubo\vslG' s 
group also observed that Fn 14 is capable of inducing the proliferation of oval cel1s 
(precursor for liver cells). Over-expression of Fn14 in transgenic mice resulted in 
hyperplasia in liver.' Cirrhosis was first identified as the result of abnormal collagen 
synthesis by fibroblasts in liver. However, the linkage between the abnormal behavior of 
fibroblasts as the effector cells and the inflammatory cells was not known in the past 
(McGee & Fallon, 1978). The observation of an elevated expression level of Fn 14 in 
liver may suggest its role in wound healing disorders and abnormal formation of fibrous 
scar tissues. 
Rheumatoid arthritis, an auto-immune disease, is characterized by over-proliferation of 
synovial fibroblasts that have a tendency to invade into cartilage and bone, forming 
fibrous scar tissue and affecting the movelnents and functions of the joints. Kan1ijo et al 
in 2008 has studied the role of TWEAK-Fn 14 in the pathology of Rheumatoid arthritis. 
The group has detected Fn 14 ex pression in RA synovial fibroblasts and reported that 
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cultured RA synovial fibroblasts have up-regulated proliferation stimulated by TWEAK. 
Anti-TWEAK and anti-Fn14 on the other hand, was shown to be able to suppress cell 
proliferation and cytokine production. The group concluded that TWEAK-Fn 14 may 
contribute to the pathology of RA by stinlulating the proliferation of the synovial 
fibroblasts and up-regulating the expression of pro-inflammatory cytokines. The role of 
TWEAK on promoting inflammation particularly acting on fibroblasts was further 
confirmed by KUlnar et al in 2009. The group studied the biological response of 
fibroblasts towards TWEA.K and obtained that it is able to induce proinflammatory 
signaling pathways through activation of TGF-beta-activated kinase 1. 
To conclude, current studies on the TWEAI{fFn 14 pathway reveal its important role in 
wound healing. TWEAK-Fn14 is now thought to be able to amplify local inflammatory 
response. Its actions also include expansion of tissue cells after tissue injury and the 
modulation of the wound healing response. Persistent up-regUlation of Fn 14 on tissue 
cells, particularly fibroblasts, is observed within the affected sites of some fibrou s 
degenerative diseases and auto-immune diseases. Evidence shows that the pathway may 
be involved in local pathologic expansion of fibroblasts and over-production of collagen 
leading to accumulation of fibrous connective tissues at the diseased sites. 
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In our study we have for the first tinle observed nearly a 3-fold up-regulation of Fn14 in 
keloid-derived fibroblasts ~ while the expression in normal fibroblasts was only Ininimal. 
This observation was in line with current studies that Fn 14 should be only minimally 
expressed by nonnal tissue cells under normal situation. Given the existing studies on 
the action of TWEAK-Fn14, we propose that over-expression of Fn14 in keloid-derived 
fibroblasts could possibility play a role in the pathology of keloid. Similar to the case of 
cirrhosis and rheumatoid arthritis derived fibroblasts, keloid fibroblasts are shown to 
have over-proliferation and over-production of collagen, which directly leads to the 
excessive scan~ing. The Fn 14 over-expression was shown to have exerted its effect on 
the mentioned diseases as previously discussed. It would be very interesting to 
investigate whether the same logic could extend to the keloid and hence possibly provide 
a brand new perspective to the pathology of the mysterious keloid scar. Furthermore, it 
could even be made a therapeutic target and provides new solutions to keloid treatment. 
2.4.7 Up-regulations of 1-'NFI~SF6B in Keloid-derived Fibroblasts 
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TNFRSF6B, more cOlnmonly known as DCR3, is a relatively new member of the tumor 
necrosis factor receptor (TNFR) superfalllily, and was first discovered by Pitti et al in 
1998. As reported by Pitti, the protein apparently lacked a transmembrane sequence and 
therefore was thought to be a soluble, secreted protein rather than a membrane 
associated molecule. The group also showed that DCR3 binded to FasL and inhibited the 
FasL activity. Yu et al (1999) discovered that DCR3 was also able to suppress 
LIGHT-mediated apoptosis by binding to LIGHT in addition to FasL. DCR3 mRNA 
was over expressed in malignant tissue such as in lung and colon cancer (Pitti et aI, 1998; 
Bai et aI, 2000). 
The linkage between over-expression of DcR3 and some pathological conditions has 
been investigated recently. In 2006, Hayashi et al was the first group to investigate the 
expression of DcR3 in synovial fibroblasts derived from patients with rheumatoid 
arthritis. The group speculated that as synovial fibroblasts derived from rheumatoid 
arthritis showed reduced apoptosis and proliferate aggressively as tumor cells, DcR3 
may play a role in the pathologies. In This group was the first to identify the expression 
of DcR3 in rheumatoid arthritis synovial fibroblasts. They have treated rheumatoid 
arthritis synovial fibroblasts with recombinant human FasL and found that they were 
resistant to Fas-mediated apoptosis. They also disrupted the expression of DcR3 in 
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rheumatoid arthritis synovial fibroblasts using DcR3 slnaU interfering RNA. The results 
showed that the resistance to Fas-lnediated apoptosis was greatly reduced. The group 
concluded that the expression of DcR3 Inay be one of the reasons for reduced apoptosis 
in synovial fibroblasts derived fro m rheulll atoid arthritis. 
As discussed earlier, fibroblasts derived fro m keloids showed altered apoptosis 
regulation, causing a proliferation- apoptosis inlbalance and may ultimately leading to 
the excessive scarring. Lu et al (2007), Chodon et al (2000) and Ladin et al (1998) all 
observed that Keloid-derived fi broblasts showed resistance to apoptosis in vitro. Chodon 
et al (2000) observed that while keloid-derived fi broblasts showed significant resistances 
to Fas mediated apoptosi s, the Fas receptor ex pressions appeared to be the salne as 
control. 
It is interesting to compare the behavior of the synovial fibroblasts isolated from 
rheumatoid arthritis and dermal fibroblasts iso lated from keloid scarring. RA derived 
fibroblasts in vitro showed increased proliferation and reduced apoptosis (Kusunoki et aI, 
2005; Liagre et aI, 2007). Clinically, RA fibroblasts have the tendency to invade into 
normal tissue, replace the function al synovial cartilage into fibrous ti ssue (Guiducci et ai, 
2005). All these observations are significantly similar to keloid fibrobl asts which also 
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showed increased proliferation, causing increase in fibroblast population in active keloid 
scars. In addition to the excessive growth, keloid-derived fibroblasts also showed the 
tendency to invade into normal ti ssue, over-producing collagen resulting in a di srupted 
skin organization and excessive scarring. Although RA and Keloid scarring are two very 
different kinds of diseases, it is striking for the similarities shared between the 
phenotypic behaviors of fibroblasts. 
In our studies we have observed a significant up-regUlation of DcR3 mRNA expression 
in keloid-derived fibrobl asts when compared to normal fibroblasts. Although the action 
of such an increase is not yet investigated in our study, it is reasonable to speculate that 
the role of DcR3 in keloid may be similar to that of rheumatoid arthritis given the shared 
similarities of fibroblasts between the two diseases. Similar to rheumatoid arthritis, 
DcR3 may be one of the reasons why keloid-derived fibroblasts exhibit resistance to 
Fas-mediated apoptosis (Lu et aI, 2007). In our microarray results, there is no difference 
in expression levels of Fas receptor in keloid and normal skin. This also agrees with 
Chodon's findings in 2000, that keloid's resistance to Fas-mediated apoptosis did not 
come from the difference in expression of Fas receptors. Some molecules may exist to 
inhibit the Fas pathway. Being a decoy receptor of Fas, localized increase in DcR3 
expressed by keloid-derived fibroblasts may COlTIpete with Fas receptor for Fas ligand, 
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and hence protect the fibrobl asts frorn undergoing apoptosis and leads to the excessi vc 
scarring. Further studies are required to confirrn the observation. 
2.5 Summary 
In this part of study we have identified 5 apoptosis-related genes expressed differently in 
keloid and normal' fibroblasts, anlongst, OPO, Fn] 4 and DcR3 have crucial roles in 
regulating the wound heali ng and j Olmune responses. This tnay suggest that in order to 
study the pathogenesis of keloid, it may be usefu l to look at the defects in the scar's 
healing response through the secretion of cytoki nes to recruit or eliminate tissue cells. 
Early in 1979, Cohen et al has studied the systemic and localized immune paranleters in 
45 keloid patients. The group demonstrated that there was significantly increased local 
immune response in keloid with an increased level of immune complex observed locally 
in the keloid lesion. However, systemic immune parameters have shown no difference 
between keloid patients and 200 controls. I(azeem in 1988 also observed elevated levels 
of immune complexes in keloid and suggested that alterations in the immune response 
may contribute to the scar fonnation. In 1990, Martin & Muir observed increased 
number of inflammatory cells infiltrating in keloid tissue when compared to normal. Ten 
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years later, Boyce et al (2000) also observed increased number of macrophages in 
between the collagen bun dles in keloid scars . There were al so significantly more T cells 
observed in keloid with a significantly higher CD4 : CD8 ratio. However, despite the 
attelTIpts to address the irntTIunological aspects associated with keloid formati on, little 
has been known about the relationship between these observations and the pathogenesis 
of keloid. Keloids are often referred to as the result of an "over exuberant" heali ng 
response. However, despite the 111any years of effort, the drivers of the abnormal healing 
response have remained unknown . 
In our studies we have observed a significant dow n-regulation of OPG in keloid-derived 
fibroblasts. In the immune system, OPG is know n to be able to attenuate 
RANK-RANKL interaction and hence down-regulate the immune response by helping 
to eliminate cells that produce pro-inflammatory cytokines. The down-regulation of 
OPG observed in keloid lnay possibly lead to the accumulation of active 
pro-inflammatory cells locall y within the scar, and prolong the local inflammation 
process. This agrees with the observations in the literature that there is an increase in the 
number of inflammatory cells found in keloid scars. Over proliferation of fibroblasts and 
over production of collagen lTIay hence be the consequence of the down-regulation of 
OPG secreted locally by fibroblasts. 
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The up-regulation of Fn 14 in keloid-derived fjbro blasts may provide another pathway 
for the excessive developlnent of scar tissue as discussed earlier. Fn14 mainly acts on 
fibroblasts by letting thenl respond to pro-inflamnlation cytokines released by cells from 
the immune system. Over expression of Fn 14 was shown to lead to over production of 
fibrous tissue and prolonged inllalnrnatiol1 . On the other hand, up-regulation of DcR3 
by keloid-derived fibrob lasts t11ay protect the cells from apoptotic signals and hence 
leads to the proliferation--eliminatjon ill1balance. 
2.6 . Conclusions 
In our studies, we have identified the up-regulation of several interesting genes in 
keloid-derived fibroblasts when compared with normal skin fibroblasts using 
MicroArray analysis. The result is confirnled with real time-PeR. All these fi ndings in 
our study are novel and they open new opportunities in the studies of keloid 
pathogenesis. We speculate the possibility of the interaction between an altered imrnune 
response in the lesion and the al tered apoptosis regulations in keloid fibrobl asts . We here 
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provide a different perspective in ke loid pathology and open many opportunities for 
potential future studies. 
2.7 Further research plans 
The differential expression of OPO, DcR3 and Fn 14 at the protein level by keloid and 
normal fibroblasts' needs to be confinned using \vestern blotting analysis. Furthennore, 
the role of DcR3 on keloid scarring can be studied in vitro by blocking the DcR3 
expression in keloid-deri ved fibroblasts and examine their susceptibility to apoptosis. In 
addition, it is also interesting to look at the expression of DcR3 in vivo by 
immunohistochemcial staining in keloid scar biopsies to confirm its clinical significance 
as a therapeutic target. 
On the other hand, Fn 14 has been reported as a therapeutic target to suppress 
inflammation in some inflamlnatory diseases such as liver cirrhosis and rheumatoid 
arthritis (Jakubowski et aI, 2005; Kall1ijo et a], 2008). Its role in keloid scarring can be 
further studied by introducing Fn 14 anti bodies into keloid fibroblast in vitro and 
compare the collagen synthesis, pro liferation and apoptosis. 
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3 Laser Interaction in Keloid Scarring 
3.1 Introduction 
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The term LASER means Light Amplification by the Stimulated Emission of Radiation. 
Lasers produce a coherent light beam of a specific wavelength. The production of a laser 
beam involves supplying energy to a cavity containing the gain medium between two 
mirrors, with one being semi-transparent and acting as the outlet of the laser beam. The 
gain medium is the material inside a laser machine that can amplify the light that enters 
the space with a characteristic wavelength when a particle is passing through it. Gain 
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mediums can be in "solid state" 'Nhich is a cOlnbination of solid crystals, or "gas s tate~', 
which contains gas molecules. The particles inside a specific gain medium can be 
stimulated when being "pu nlped'~ vvi th energy and some of their electrons are excited to 
a higher quantum level. The electrons return to the ground state by emission of a 
characteristic wavelength of light reflecting the change in the energy state, a single 
wavelength light beam is hence produced. The single wavelength light beam will be 
reflected back and, forth between two l11 irrors and each time passing through the gain 
medium, and amplification of Jight is thus achieved. The polarity of reflected light is 
also synchronized and the coherent laser 11ght beam escapes through the 
semi-transparent mirror. The range of visible light is 400 nm-780 nm, which means 
lasers with wavelengths falling outside this range cannot be seen by the human eye. 
Lasers have been used clinically for 1110re than 40 years now (Tanzi et aI, 2003). Their 
application in treating abnonnal scars started in the mid-1980s. Common types of lasers 
are summarized as follows: 
Gain Medium Type of laser Wavelength Spectrum 
Argon gas state 488/514nm blue-green 
Nd:YAG solid state 1064/532nm infrared/ green 
Organic Dye liquid state 585-595nm yellow 
Er:YAG solid state 2490nm infrared 
Carbon Dioxide gas state 10600nm infrared 
Table 2. Different types of laser with different gain mediums 
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Figure 7. The light spectrum 
3.1.2 Biological Effects of Laser on Skin 
Tissues consist of cells embedded in an extracelluar matrix (ECM). Measured by weight, 
the extracellular matrix mainly consists of water and collagen (Vogel & Venugopalan, 
2003). Some molecules are also present in smaller amount such as elastin, 
glycosaminoglycans, glycoproteins and cell adhesion proteins together to give the 
characteristic physical and biological properties of the ECM (Silver, 1987). 
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In human skin, collagen accounts for approx 11l1atel y 30 % of the total weight wi th wuter 
accounting for nearly all the rest (CrJig, 1975). Therefore, studies on laser-collagen and 
laser-water interaction wi ll give Cl picture of laser- Inatrix interaction (Vogel & 
Venugopalan, 2003). 
3.1.3 Laser-matrix interaction 
The laser matrix interaction is slull lnarized in a book written by Niemz in 2004. 'A'hen 
laser energy is delivered to skin, there will be a rise in temperature and resulting -in a 
gain in kinetic energy of collagen fibrils. Denaturation of collagen refers to the situation 
when collagen has gained enough kinetic energy to overcome the forces that keep the 
fibers in place, and the intact helical structure relaxes, hence losing mechanical strength. 
The maximum temperature the collagen in skin can tolerate depends on the num ber of 
crosslinks present in the collagen molecules (Niemz, 2004). Generally, older people 
have more crosslinks in ski 11, and therefore, can tolerate a higher energy than younger 
individuals when exposed to laser (Niemz, 2004). Note that collagen denaturation not 
only depends on the thermal effect introduced by a particular type of laser, but also the 
pulse duration of laser. A shorter pulse of laser, the higher the maximum temperature 
collagen can tolerate (Caroll & I-Iumphreys, 2006). 
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Light of different wavelength will be differently absorbed by different molecules in skin. 
The ability of different molecules to absorb energy of a particular wavelength is 
measured as the absorption coefficient. The absorption coefficients of water, 
hemoglobin, melanin and collagen are summarized by Vogel and Venugopalan (2003) in 
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Figure 8. The absorption coefficients of different tissue components 
As shown in this figure, outside the visible range (wavelength = 400 - 780 nm), light 
energy is mainly absorbed by water, and collagen; while inside the visible range, energy 
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is .mainly absorb by melanin, oxy-helTIoglobin and deoxy-hemoglobin. Unlike UV light, 
which can be largely absorbed by DNA in the cell and can directly cause DNA 
fragmentation and potentially genetic alternation , visible range laser mainly asserts its 
effect through a thermal effect. The depth of penetration of laser into skin depends on 
the wavelength, as different wavelength will have absorption peaks for different 
elements. Longer wavelength (like Nd:YAG 1064 nm) laser is poorly absorbed by water, 
and other pigments (hemoglobin, tnelanin) in skin, and therefore it has highest 
penetration into skin (Vogel & Venugopalan, 2003). Research done by Goh in 2003 
showed the penetration depth of Nd:YAG 1064 nm laser is 6 - 7 n1m. 
Laser energy in the visible range, such as 585 nm PDL and 532 nm frequency doubled 
Nd:YAG laser is greatly absorbed by helTIoglobin and melanin in siGn, and therefore 
onlY 'have a penetration depth of less than 0.7mm (Hohenleutner et aI, 1996). It is widely 
hypothesized that the action of 585 nm PDL on hypertrophic scar is by selectively 
delivering energy to the microvessels which damages the blood supply to the highly 
proliferative hypertrophic scar and hence forcing it to regress (Bowes et aI, 2002; Parrett 
& Donelan,2009). 
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3.1.4 Laser-cell interaction 
Unlike the laser-matrix interaction, the laser-cell interaction is less well understood, and 
it is believed to be more complex than the laser-nlatrix interaction which only involves 
biophysical phenomenon. The effect of laser on cells depends heavily on the wavelength 
and the pulse duration. For example, red laser (around 700 nm) is equally absorbed in all 
sub-cellular regions of a cell and therefore can dalTIage the whole cell unselectively 
(Sheetz, 1998). Shorter wavelength blue green laser (around 600 - 500 nm), on the other 
hand, is absorbed selectively by SOlne sub-cellular regions and therefore can be used 
with more specific biological functions (Sheetz, 1998). Laser pulses with longer pulse 
duration will greatly increase the temperature sU1Tounding the cell. Significant 
temperature rise will kill the cell directly via thennal effect (Caroll & Humphreys, 2006). 
With shorter pulse duration (e.g. in nanoseconds), the environment surrounding the cell 
can dissipate the heat very quickly (Keller et aI, 2001). Temperature rise will hence be 
localized in sub-cellular regions where the absorption is high (Sheetz, 1998) 
Laser energy mainly interacts with cells Inainly via two different mechanisms: firstly by 
creating shock waves on cell membranes and hence altering its structure (Sheetz, 1998); 
and secondly via natural chromophores such as the respiratory organelles (Vogel & 
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Venugopalan, 2003; Sheetz ~ 1998). A si ngle cell experiment on exposure of pulsed Nd: 
YAG 532 nl11 derTIonstrated that the .laser can create a transient alteration in electrical 
activity of the outer membrane of the cell and lTI ake the membrane more permeable to 
exogenous molecules (I( itzes & Berns, 1979) . Ziegler and Chiu in 2009, and Shelby et al 
in 2005 have demonstrated that laser can also alter cell viability mainly via the 
disruption of the plasma n1el11brane, and can lead to necrosis or apoptosis depending on 
the radiation mechanism and energy. 
3.1.5 Clinical Use of Laser in treating Keloids 
Lasers have been used clinically to treat keloid and hypertrophic scars for more than 
twenty years. The following paragraphs summari ze the timeline for the use of several 
lasers on scars and their efficacy. 
The 1980s 
The use of laser in treating keloid scars started in the mid 1980s. Castro et al (1983) 
were the first ones to observe a decreased coll agen production in normal fibrobl asts after 
1064 nm Nd:YAG laser treatment, and later started the trend of research of laser effect 
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on abnormal scars. Apfelberg et al (1984) was the first group to study the use of the 
argon laser and carbon dioxide laser exci sion of earlobe keloids of 13 patients. In their 
study, however, only 1 patient responded to the treatment while the remaining 12 
showed no improvements. Abergel et al (1984) treated keloid fibroblasts cultures with 
Nd: YAG 1064 nm laser and observed decrease in collagen production. In their clinical 
studies 8 patients with keloid lesions \vere treated with nondestructive laser dosage and 
after 3 years of follow up, the scars were flattened and softened. 
Hulsbergen-Henning et al (1986) used "di sappointing" to conclude their results in a 
clinical study involving 45 patients with keloid scars using Argon laser. Only 3 showed 
positive results while 28 showed poor results in the study. The group observed shrinkage 
of keloid immediately after treatment but the scar recurred several days after. This result 
however, supported Apfelberg ' s poor resu Its with the Argon laser on 1984. 
The carbon dioxide laser's effects on keloids are not promising either. In ] 989, Stern 
and Lucente used the carbon dioxide laser to excise 23 earlobe keloids and 17 recurred 
after the surgery, and the group concluded that carbon dioxide laser excision failed to 
lower the recurrence rate of keloids. 5 years after the initial failure of treating earlobe 
keloid with carbon dioxide and Argon, Apfelberg et al tried the CO2 laser excision again 
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in 1989 and obtained equally disappointing results. 8 out of 9 keloids in earlobe, back or 
trunk region recurred 10 - 22 lTIonths after treatnlent, and Apfelberg concluded the use of 
CO2 laser on keloid scar excision as failure. Norris (1991) also reported similar results 
with CO2 laser excision and concluded the modality failed. 
To conclude, the use of Argon laser in treating keloid scars and keloid excision using 
CO2 is not satisfactory. Nd:YAG 1064 nn1 seemed to have some positive effect on 
keloid scars; however, its effect has not been studied fully. From the mid 1990s, 
scientists had turned their attentions to another type of laser- the 585 nm pulsed dye 
lasers (PDL). The effects of PDL on hypertrophic scars were particularly promising and 
this laser is widely used clinically nowadays. However, the effect on keloid scars is not 
so predictable. 
The 1990s 
In 1995 Alster et al treated median sternotomy keloid scars with 585 nm PDL. The 
treated group showed improved texture. In 2000, Connell and Harland treated 10 
patients with recalcitrant keloid scars with 585 nm PDL followed by intra-Iesional 
steroid and the combined effect was reported as satisfactory. When earlier results 
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appeared prol11isi ng, Paquet et al (200 1) tried to i Inprove the appearance of keloid usi ng 
585 nlll laser and found that there \vere no significant effect on erythema of keloid. 
Manuskiatti and Fitzpatrick in 2002 revealed that there were no significant differences in 
treatment outcome between 585 nm PDL and intralesional steroid treatment; however, 
585 nl11 PDL was relatively free from adverse effects. Kuo et al (2004) recruited 30 
patients with keloid and treated theIn \vith 585 nln laser at intervals of 2 months vvith 
mean fluence of 14 J/cm2. Result revealed that 26 patients showed greater than 50 % 
regression of keloid after twelve months. The group also observed that more treatment 
received under regular time intervals would yield better treatment outcome. 
Unlike the positive outcome in treating hypertrophic scars, there are no agreements on 
the efficacy of laser on keloid scars. The discrepancies in results can be due to the lack 
of large scale clinical trials and the lack of quantitative and cotnparable outcome 
measures. Also, the wealth of parameters that are involved in the laser treatment 
complicates the evaluation of results. Even for the same type of laser used, different spot 
size and intensity can result in very different outcomes. It is generally observed that 
higher energy will yield better result than lower energy. But if the energy is too high it 
will increase the risk of side-effects (Bouzari et aI, 2007). 
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Nd: Y AG 532 nln Laser 
The Nd: YAG 532 nlTI laser is widely used clinically in tattoo removal and treatment of 
pigmented lesions due to its high absorption coefficient by the pigment melanin in sIGn. 
The wavelength of Nd:YAG 532 nn1 laser is close to 585 nm PDL, and therefore, SOlne 
studies have compared the effects of 532 nm and 585 nm on scars. Bowes et al (2002) 
recruited 10 patients with hypertrophic scars and divide each scar into areas of equal size. 
One of these areas was treated Vvith 585 nm PDL, 1 Omm spot size, 3.5 J/cm2 and pulse 
duration of 450 f.ls; one treated with frequency doubled QS Nd:YAG 532 nm laser, 3 
mm spot size, 2.8 J/cm2 with pulse duration of IOns; and one was left untreated acting 
as control. The results showed significant ilnprovement of all treatment groups when 
compared to control. But there were no significant difference in treatment outcome 
between 585 nm PDL and QS 532 nm laser. The group concluded that QS Nd:YAG 532 
nm laser is at least as effective as 585 nm PDL in treating hypertrophic scars. 
The clinical effects of 585 nlTI laser on scars have been relatively well studied. However, 
there are few studies designed to study the effect of 532 nm laser on keloid scars. 
Therefore, studying the effect of 532 nn1 laser on such scars becomes important as it 
may potentially provide further strategies to treat this clinical challenge. Also, the 
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mechanistns of how laser exerts the biological effects on the cells are still yet to be fully 
discovered. Previous studies by our group (Poon et aI, 2005) have evaluated the effect of 
QS Nd:YAG 532 nm laser on normal fibro bIasts n10nolayer culture using a sub-lethal 
dosage. Our group has obtained the viability of normal fibroblasts under different 
fluence of laser exposure, and determined the sub-lethal dosage on monolayer nonnal 
fibroblasts culture. Our group observed the increase in SCF, HGF and b-FGF gene 
expression in fibroblasts under repeated sub-lethal laser exposure by RT -PCR analysis. 
In our previous study, although the other biological effects of Nd:YAG 532 nln laser on 
keloid fibroblasts were not specifically exaluined, it clearly revealed the ability of the 
laser to affect cell behavior by regul ati ng gene expression. 
Therefore, it would be of interest to explore the effect of the laser with higher intensity 
in order to reveal a better picture of Nd: YAG 532 nm laser's potential in treating keloid 
scarrIng. 
3.1.6 Methods of Laser Research on Keloids 
In order to study the laser-cell interaction for clinical applications, experimental models 
have to be developed to luimic the biological environment of the cells of the skin. Many 
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different Inodels have been developed to serve thi s purpose. The most common ones are 
being 1) monolayer cell model 2) 3D ti ssue engineered model and 3) tissue biopsies. 
The lTIonolayer cell model 
This is the first, simplest and most direct model in evaluating the results of laser on 
fibroblasts. Cells were seeded in culture di shes or wells. Medium was relTloved just 
before laser radiation and was replaced quickly afterwards. In this way, the cells were 
exposed to laser directly free of the interference with other factors. The results were 
clear and could easily be evaluated quantitatively. Cells after treatment could be easily 
obtained for viability or proliferation experiments. Protein secretion could also be 
analyzed through the collection of the conditional culture medium. Previous studies by 
our group (Poon et aI, 2005) on the effect of Nd:YAG 532 nm laser have used thi s 
monolayer cell model. However, monolayer cultures may be over-simplified the 
complex biological environment of cell s. Results obtained thus may not be of direct 
clinical relevance. 
The 3D tissue engineered model 
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Keloid scarring is a unique condition in hu mans and cannot be found in any other 
animals. Therefore keloid research is particularly challenging because of the lack of 
aninlal models. Using a 3D tissue engineered 11l odel rnay be useful for the studies on 
laser-tissue interactions without invol ving as significant ethical problems as taking 
biopsies from keloid patients. In 2005, Chiu et al constructed a raft that involves mixing 
fibroblasts in a collagen lTIatrix \vith keratinocytes seeding on the top for laser 
experiments. Normal and keloid fibroblasts and keratinocytes were chosen for the 
construct, and the effect of photodynamic therapy was studied. Photodynamic therapy 
involved introducing a photosensitizing agent (5-amino levulinic acid) which will absorb 
the laser energy and enhancing the laser effect. The viability of cells after laser treatment 
was evaluated using confocal microscopy. The group observed that the viability of 
keloid fibroblasts was higher than that of nortTIal fibroblasts. 
This 3-D tissue engineered model is a sophi sticated model in laser research that 
simulates the natural archi tecture of the skin and is of potential clinical relevance. 
However, more than one type of cells was involved in this model and there were far 
more variables to control than that in monolayer cell cultures. For example, the coll agen 
density and the cell density of fibroblasts and keratinocytes have to be carefully 
controlled in each sample. Qualitative exaJnination of results may be more useful for this 
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1110del such as hi stological stainin g. I-1<. \vever, quantitative biological paral11eters such as 
protein expression are more difficult to evalu ate in this lllodel. 
Ti ssue biopsies after laser treatment 
Following positive clinical results of 585 nl11 PDL treatment on keloid in 2004, Kuo et al 
performed studies on the nlechanislll of keloid regression induction by 585 nm PDL. In 
2005 , the group obtained punch biopsies of keloid scars from 10 patients before and 7 
days after laser treatment (mean fluence equal to 14 J/cm2 as in their previous clini cal 
study). They then looked at the proliferation of keloid cells by PCNA, the apoptosis by 
TUNEL array and cleaved caspase-3, and l\1AP ki nase activation by p38, ERK and JNK 
expressions using iml11uno-histochemical staini ng. The group reported a decrease in 
PCNA-positive cells after laser treatment, an increase in TUNEL-positive cells and a 
moderate increase in caspase-3 activation. Expression of ERK and p38 was also 
increased; however, the level of JNI( stayed more or less the same. The group concluded 
that 585 nm laser suppressed keloid formation by suppressing proliferation and 
enhancing apoptosis of the fibroblasts. 
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Obtaining punch biopsies directly at the site of treatlnent would be the best way to reveal 
the laser effect on tissue. Besides identifying the expression levels of proteins of interest 
by immuno-histochemical staining, the coagulation depth reached by the laser and the 
subsequent extracellular matrix remocleling would be shown clearly. However, 
histochemical studies are qualitative measurement of treatment outcome. The number of 
positive cells can be counted under microscope and compared with different treatment 
groups. But the total number of cell was not known. Therefore, we do not know what 
percentage of cells have undergone apoptosis . A.lso, due to the limited punch biopsies 
researchers can obtain from patients, the tilne response of cells on laser cannot be 
studied in detail. The group did not provide reasons for choosing 7 days post treatment 
as the time for evaluation of treatlnent effect. However, their studies still provide useful 
information for the studies on laser tissue interactions. 
It may be also worth pointing out that punch biopsies introduce wounds to the keloid 
patients, and may have the risk of inducing further keloid scarring, there may be some 
ethical issues involved in such studi es. Obtaining patients consent to participate in such 
studies may also be particularly difficult. 
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To conclude, there are a nutnber of n1ethods developed for studying the laser cell 
interactions, each with their advantages and disadvantages in the experimental designs. 
As a first step to study the biological effect of Nd: Y AG 532 nm laser on keloi d-derived 
fibroblasts, it is preferable to start with the silnple and direct monolayer cell model so 
that the results are clear and easily measurable. If a positive result is observed, lTIOre 
sophisticated models such as the 3D ti ssue engi neered model or even tissue biopsies 
could be used to obtain lTIOre concrete results for clinical applications. 
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3.2 Material and method 
3.2.1 Cell Culture 
Fibroblasts culture was obtained as described previously in section 2.2. J 
3.2.2 Laser radiation 
Keloid scar fibroblasts were seeded on 6-vvell plates at 1 X 10s cells per well and 
cultured in DMEM + 10 % FBS until 80 % confluence. Culture medium was then 
removed and cells were washed twice vv' ith PBS prior to laser exposure at energy 0.55 
and 1.0 J/cm2 in duplicates. 
The laser machine used in th is study was Versapulse Coslnetic Laser System (coherent 
medical group). The laser wa a Q -switched frequency doubled Nd:YAG 532 ntn laser 
with pulse width of 4 ns. The 111achine could de li ver a maximum energy of 200 mJ 
through a handpiece with adjustable spot sizes of 2,3,4,5 and 6 mm in diameter at 
frequency 1,24 and 10 Hz or single shot. The handpiece was fixed using a clamp and 
the cell culture in a 6-well plate was put on top of a rotor right beneath the handpiece. 
The 6-well plate was placed in an inverted position to ensure direct exposure of the cells. 
A red piece of cardboard was placed underneath the 6-well plate to reduce reflection. 
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DMEM + ] 0 % FBS was added to each \vell imnlediately after laser treatment. 
3.2.3 Trypan blue exclusion 
Two keloid fibroblast ce ll 1i nes \vere used in the experiment in triplicate. At 24 and 48 
hours after laser treatment, cell viability was rneasured using trypan blue exclusion 
Inethod. The cells were col lected by trypsinization using 0.5 mL 0.25 % trypsin - 1 mM 
EDTA (Gibco BRL) for 3 minutes. 1 ~ll of the cells were stained with 1 f..ll of 0 .4 0/0 
trypan blue (Sigma) solution. The number of viable (not stained) and dead (stained) 
cell were counted and presented as the percentage over total number of cells. Statistical 
significance was tested using 2-sided T -test against control with n=6. 
3.2.4 Annexin-V flow cytometry 
Two keloid fibroblast cell lines were used in the experiment in triplicate. At 24 and 48 
hours after laser treatment, the cell s were harvested using 0.25% trypsin-EDTA (Gibco 
BRL) and washed twice with PBS. Floating cells that detached from cultures vessels 
during this period of culture after laser exposure were also collected by centrifuging the 
culture medium. Combined cell pools were finally resuspended in Annexin-V -Fluos 
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labeling solution. 
Diluted labeling solution \vas prepared by ll1ixing 40uL Annexin-V -Fluos labeling 
regent, 40 f.ll Propidium iodide solution in 2 1111 Incubation buffer (Annexin-V -Fluos 
staining kit, Roche). 250 J.11 of the labeling solution was used to resuspend the washed 
cell pellet and was incubated for 15 minutes in room temperature. The cells were then 
analyzed on a flow cytometer. Statistical significance was tested using 2-sided T -test 
against control with n=6 . 
3.2.5 BrdU cell proliferation assay 
Two keloid fibroblasts cell lines were used in the experiment. At 24 and 48 hours after 
laser treatment, cell proliferation activity was measured by cell proliferation ELISA, 
BrdU kit (Roche Molecular Biochelnicals). 100 ~l BrdU labeling reagent was added to 
each well and incubated for 4 hours in humidified CO2 incubator at 37 QC. Attached cells 
were fixed with Denfix solution for 30 luin and then incubated with anti-BrdU antibody 
for 2 hours at room temperature. After washing three times with PBS, 
chromogen-containing substrate was developed for 30 min and the reaction was 
terminated by the addition of 500 fil lM H2S04. The chemiluminescence was measured 
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at 450 nln using 690 nm as a reference. Results \vere expressed as the relative cell 
proliferation activity cOlnpared to shanl-irradiated controls. Statistical significance was 
tested using 2-sided T-test against control \vith n=2. 
3.3 Results 
3.3.1 Cell Viability of Keloid Fibroblasts After 532 om Laser Treatment 
Under the laser condition at 3 mm/s rotor speed, S mm spot size and 1 Hz pulse 
frequency, fibroblasts in 6 well plates were exposed under 0, 0.55 and 1.0 J/cm2 laser. 
Trypan blue exclusion was perfonned for the assessment of cell viability, flo \v 
cytometry of Annexin V/PI for apoptosis and BrdU assay for cell proliferation were 
performed in triplicates for 2 keloid fibroblasts cell lines. The results are shown as 
follows. 
Cell Viability by Tryphan Blue Exclusion 
Control 0.55J/cm2 1.0J/cm2 
24 hours 93.00%1 91.98%1 86.86%1 
SO 2.51 % 2.13% 4.52% 
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Figure 9. Viability of keloid fibroblasts after laser treatment 
By using trypan blue exclusion, the viability of keloid fibroblasts of all groups at 24 
hours was above 85 0/0, with the control and 0.55 J/cm2 treated group greater than 90 0/0. 
At 48 hours, the control and 0.55 J/cm2 treated group still maintained viability greater 
than 90 0/0, while the viability of 1.0 J/ cm2 dropped sharply to around 70 %. Under 
2-sided T -test, the difference between 1.0J/ cm2 treatment group and the control at both 
24 and 48 hours has statistical significance. 
90 
3.3.2 Apoptosis VS Necrosis In Ptrcentage Of CeH Death 
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Apoptotic verses necrotic cells after laser QS Nd:YAG 
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Figure 10. Percentage of apoptotic and necrotic cells after laser treatment 
For apoptotic verses necrotic cells, at 24 hours, less than 5 % of cells were undergoing 
apoptosis for the control and 0.55 J/cm2 treated group; while for 1.0 J/cm2 treated group, 
there was around 7 % of apoptotic cells, under 2-sided T-test, the difference was 
statistically significant. At 48 hours, the percentage of apoptotic cells was around 3 % 
for the control and the 0.55 J/cm2 treated group, while for 1.0 J/cm2 treated group, 
around 18 % of keloid fibroblasts were apoptotic, the difference was statistically 
significant. Also, for the 1.0 J/cm2 treated group, the percentage of necrotic cells was 
9 %, only half of the apoptotic cells. 
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3.3.3 Cell proliferation after 532 nm laser treatment 
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Cell Proliferation by BrdU assay 
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The above BrdU readings were nonTlaJi zed by dividing the treatment groups readings 
over the control group reading. i-\t 24 hours, the proliferation rate for the 0.55 J/cm2 
treatment group was 1.4 fold as co[npared to the control 'whereas the 1.0 J/cm2 treatment 
group was only 60 % of the contro l. J\t 48 hours , the cell proliferation in both 0.55 J/cln 2 
and 1.0 J/cm2 treatment groups dropped slightly ;}S c0111pared to the control. 
3.4 Discussions 
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3.4.1 Discussions on Optimization of Laser Parameters 
The laser machine used in this study is Q-switched frequency doubled Nd: Y AG laser at 
532 nm, with pulse width 4 ns, from Versapulse® Cosmetic Laser System (Coherent 
medical group). The diameter of the laser pulse is adjustable at 2,3, 4, 5 and 6 mm, 
delivering total energy ranging from 100 mJ to 200 mJ per pulse. Under this system, 
given the same total energy, smaller the spot size, higher the energy density of each laser 
pulse. For example, a 5 mm spot with energy density equals to 1.0 J/cm2, and a 4 mm 
spot with an energy density equals 1.5 J/cm2, will deliver the same total energy of 200 
mJ per pulse. 
Smm 
1.0J/cm2 1.51/cm2 
Figure 12. Relationship between spot size and laser energy density 
In our experiment, the laser probe of the Versapulse laser machine is fixed above a rotor 
using a clamp. The culture plate is placed on top of the rotor that can move at a constant 
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speed of 3 mmls in a sequential motion row by row. The rotor will advance by 3 mm at 








Figure 13. The experimental set up of laser treatment 
The pattern of the delivery of laser pulses depends on the frequency of pulse deli very 
(number of pulse delivered per second) and the spot size. If a laser pulse of 3 mm in 
diameter is delivered at a frequency 0.5 Hz, there will be a pulse every 6 mm and the 
spots would be too far apart, with 3 mm of space in between two pulses being unexposed. 
If the frequency was too high (say 10 Hz), there will be overlapping of laser pulses and 




Too low frequency Too high frequency 
Figure 14. The relationship of laser shots frequency and cell exposure 
An even coverage of laser radiation to the cells is the key to obtain a repeatable and 
measureable result. Following careful calculation, the 5 mm spot size and the 1 Hz pulse 
delivery were chosen as the optimal laser parameter. The laser pulses were slightly 
overlapped in comparable amount both vertically and horizontally. Each cell is exposed 
to laser without too much overlapping. Several other spot size and frequencies were 
tested in this study, the 5 mm spot size with 1 Hz pulse frequency was observed to give 
the most consist results. 
Figure 15 The optimal laser parameters 
Another point to note was that it was ideal to perform the experiment under one single 
spot size because when the spot size was changed, the frequency also needed to be 
changed, and the overlapping areas would not be the same. Therefore, results obtained 
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under different spot sizes might not be comparable. Using the 5 mm spot size, the 
maximum and minimum energy density could be achieved was 0.55 to 1.0 J/cm2. As 
established in our previous study by Poon et al in 2005, 0.8 J/cm2 was the cutting line for 
sub-lethal and lethal dosage on normal fibroblasts after QS Nd: YAG 532 nm laser 
treatment for 24 hours using MTT. Increasing the energy density beyond 0.8 J/cm2 
would yield a sharp decrease in viability while below 0.8 J/cm2 the cell viability was 
high. The range 0.55 - 1.0 J/cm2 offered by the 5 mm spot size well covered the lethal 
and sub-lethal transition region and hence would give more information of cell behavior 
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Figure 16. Cell viability under different laser energy density 
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3.4.2 Discussion on the Biological effects of Nd: YAG 532 nm laser 
3.4.2.1 l)ecreased viability in the 1.0 .1/C1112 treatment group at 48 hours 
In our studies keloid-derived fibroblasts were treated with QS Nd:YAG 532 nm laser of 
two energy levels: the sublethal 0.55 J/cm2 dosage and the lethal 1.0 J/cm2 dosage. As 
shown in our cell viability results, the 1.0 J/cm2 treatment group showed the lowest 
percentage of viability at both 24 and 48 hours. While the viability of the 0.55 J/cm2 
treatment group was not different from that of the control, the viability of the 1.0 J/cm2 
treatlnent group at 24 hours is 87 %, implying that 13 % of keloid fibroblasts were kill 
within the first 24 hours after laser treatment. Interestingly, at 48 hours, the viability 
further dropped to 72 %, meaning that a further 15 % of keloid-derived fibroblasts died 
within 24 to 48 hours after laser treatment. Ziegler and Chiu in 2009 observed that cell 
death via necrosis foUowing laser radiation should occur immediately after the treatment 
(within 24 hours). Therefore, the delay in cell death occun·ed at 48 hours after treatment 
may not be contributed by necrosis alone. 
3.4.2.2 Increased apoptosis in the 1.0 J/cm2 treatment group 
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The ability of Nd:YAG 532 nm laser to induce apoptosis on keloid fibroblasts could be 
revealed more clearly by the flow cyt0111etry using Annexin V vs PI. Both the 0.55 J/cm2 
treatment group and the control group showed apoptotic cell of around 3 % - 4% of total 
cell number at both 24 hours and 48 hours after treatment. The percentage of necrotic 
cells was also around 3%. 
For the 1.0 J/cm2 treatlnent group, at 24 hours, the percentage of necrotic cells was 
around 5 0/0, meaning only less than 2 % more keloid fibroblasts were killed by the laser 
under necrosis at 1.0 J/cm2 when cOlnpared with control. However, at 48 hours, a 
striking 18 % of cells were apoptotic in the 1.0 J/cm2 treatment group (p=O.O 1). The 
results also revealed the tilne course of apoptosis following laser treatment. Between 24 
hours to 48 hours, around 10 % more cells were undergoing apoptosis. This observation 
agreed with the literature that while necrosis is an ilnmediate process following cell 
damage, cell death via apoptosis would take longer than 24 hours (Ziegler and Chiu, 
2009). 
This was a fascinating observation because keloid scarring is believed to be related to an 
over-reacti ve wound healing response for a prolonged period of time leadi ng to the 
excessive scarring. Any treatments that can introduce cell death by necrosi s, for instance 
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surgical removal, will have the risk of stimulati ng the inflammation respon se and lead to 
further scarring. Apoptosis on the other hand, is a quiet way of cell elimination without 
involving the sin1ulation of the wound healing cascade. Utilizing the apoptosis pathway 
to eliminate keloid fibroblasts would be one of the ideal ways of treating Keloids. In this 
study we determined that Nd:YAG 532 nm laser is capable of inducing a significant 
portion of keloid fibroblasts to undergo apoptosis (p=O.Ol), with the necrotic cells 
portion relatively small. This indicated the great potential of laser to be developed into 
an effective treatment strategy for keloid scarring. 
3.4.2.3 Increased proliferation in the 0.55 J/cm2 treatment group 
The BrdU assay on cell proliferation had revealed an interesting effect of the 0.55 J/cm2 
laser. At 24 hours, while the proliferation of the 1.0 J/cm2 treatment group was only half 
of the control group, the 0.55 J/cm2 treatment group showed 40 % more proliferation 
than the control. This may possibly suggest that lower dosage of 532 nm N d: Y AG laser 
was capable of inducing cell proliferation. Also, at 48 hours, the flow cytometry result 
also showed a significantly lower percentage of necrotic cells in the 0.55 J/cm2 treatment 
group when compared with control. This provided very useful information on the 
clinical use of the laser. Practitioners have to be careful in choosing a sufficient dosage 
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for treating keloid. If the dosage is too lovv, the laser may induce proliferation of the 
keloid fibroblasts and may potentially worsen the situation. 
3.5 Summary and COllclusion 
As discussed in chapter 2, Keloid scarring is a very challenging clinical situation. The 
recurrence problem is particularly difficult to deal with. Many treatment strategies have 
been developed but each of them has their own benefits and drawbacks. 
The fibroblasts derived froln keloid lesions demonstrate reduced apoptosis. This is 
believed to be one of the reasons for the formation of keloid scars due to the ineffective 
elimination of cells . However, treatment methods that look to eliminating the cells and 
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the excessive scar tissue by creating wounds \\li1l activate the inflamlnatory response and 
can potentially stimulate further scar formation. 
Treatment strategies targeted to induce apoptosis in keloid tnay be effective in 
stimulating keloid regression, and may reduce the chance of recurrence. The currently 
used treatment strategies based on induction of apoptosis is the electron radiation. 
Unlike laser, which is a neutral light bealn; electron radiation is highly ionizing and can 
cause considerable dalnage to the DNA of the cells. Electron radiation can be effective 
on inducing apoptosis in keloid: however, concerns are whether such radiation win 
eventually lead to malignancy. 
The use of Nd: Y AG 532 nln laser is an elllerging treatment modality for keloid scatTing 
and has been shown to be effective in treating keloid scars clinically. It is a relatively 
safe method with minimal side effects when compared to other treatment strategies. 
However, the biological n1echanisms on keloid fibroblasts have not been established yet 
in the literature. In this study, we have observed that Nd: YAG 532 nm laser was 
capable of inducing apoptosis in keloid-derived fibroblasts. More importantly, a 
relatively insignificant percentage of cell were necrotic under laser treatment, Ineaning 
that the laser can induce apoptosis within a keloid lesion and triggers minimal 
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inflanlmatory response. It can potentially develop into a treatment modality with low 
chance of recurrence. 
The most effective energy level of Nd: YAG 532 nrn to be used in treating keloid 
fibroblasts was observed to be 1.0 J/cm2 in our study. Although the energy level 
received will be different in lTIOno]ayer cell culture and the skin, it provides useful 
infonnation that by optimizing the treatrnent parameter, the laser can deli ver its best 
treatment results. It is also worth noting that when the laser is used clinically, it would 
be essential to make sure the dosage used was adequate in order to prevent stimulation 
of keloid proliferation. 
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3.6 Further research plans 
In this study, the Nd:YAG 532 nm laser was delTIonstrated to be effective in inducing 
apoptosis in keloid-derived fibroblasrs in a monolayer cell culture model. This model is 
simple and straight forward however the relevance to clinical conditions remains 
uncertain. 
Therefore, more sophisticated lTIodels such as 3D tissue-engineered models may be used 
to reveal more information on the biological effects of the laser. 
In chapter 2, the differential expression of apoptotic genes in keloid fibroblasts versus 
normal fibroblasts has been demonstrated, and their roles in the keloid pathology have 
been discussed. Whether laser irradiation can alter the expression levels of the five 
apoptosis-related genes identified in keloid fibroblasts needs to be further elucidated. 
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4 COI1ClllSiollS 
In this study, the expression profile of apoptosis·-related genes in keloid scar and normal 
skin-derived fibroblasts was examined using rnicroarrays. Five apoptosis-related genes 
were identified to be differently expressed. OPG, Fn14 and DcR3 have been reported to 
play important roles in the regulation of wound healing and immune response. This 
finding not only opens new opportunities for the study of keloid pathology, it may also 
provide a different perspective in the pathogenesis of keloid scarring \vhich may help the 
development of some new treatment modalities. 
Laser treatlnent is one of the emerging treatnlent methods for keloid scarring. It is 
relatively safe and has minilnal side effects as compared to other treatnlent strategies. 
The biological effects of the Nd:YAG 532nm laser, including proliferation, apoptosis 
and necrosis, on keloid fibroblasts have been investigated in this study. It is observed 
that the Nd: Y AG 532 nm laser was capable of inducing apoptosis in keloid-derived 
fibroblasts. Of note the percentage of cells undergoing necrosis after the laser irradiation 
was relatively small, indicating that this laser rnay be capable of inducing apoptotic 
instead of necrotic cell death in keloid lesions, and hence triggering only nlinimal 
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infla lll lllatory re'-pon e. ThlL it 1l1ay b de\ ' I 1 cl a~ a tr~~ltlllent 1110dal ity \v ith l o \~ 
chance of recurrence of k loid . 
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